

STUDY OF BACTERIAL AND PARASITIC PROFILE OF  
ACUTE DIARRHOEA IN CHILDREN UNDER FIVE YEARS OF  
AGE WITH SPECIAL REFERENCE TO DETECTION AND  
CHARACTERIZATION OF ROTA VIRUS

*Dissertation Submitted to*

**THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY**

*in partial fulfillment of the regulations*

*for the award of the degree of*

**M.D. (MICROBIOLOGY)  
BRANCH – IV**



**GOVT. STANLEY MEDICAL COLLEGE & HOSPITAL  
THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY  
CHENNAI, INDIA.**

**APRIL 2012**

## **CERTIFICATE**

This is to certify that this dissertation entitled “**STUDY OF BACTERIAL AND PARASITIC PROFILE OF ACUTE DIARRHOEA IN CHILDREN UNDER FIVE YEARS OF AGE WITH SPECIAL REFERENCE TO DETECTION AND CHARACTERIZATION OF ROTA VIRUS**” is the bonafide work done by **Dr.K.SUBHA** in the Department of Microbiology, Govt. Stanley Medical College & Hospital, Chennai, in partial fulfillment of the regulation for **M.D. (Branch - IV) Microbiology** examination of the Tamil Nadu Dr.M.G.R.Medical University, Chennai, to be held in April 2012.

**Prof.Dr.R.SELVI, M.D.,**  
**DEAN i/c**  
Govt.Stanley Medical College and Hospital  
Chennai-600 001

**Prof.Dr.R.SELVI, M.D.,**  
Professor and Head i/c  
Guide  
Department of Microbiology  
Govt.Stanley Medical College  
Chennai-600 001

## DECLARATION

I, **Dr.K.SUBHA**, solemnly declare that this dissertation “**STUDY OF BACTERIAL AND PARASITIC PROFILE OF ACUTE DIARRHOEA IN CHILDREN UNDER FIVE YEARS OF AGE WITH SPECIAL REFERENCE TO DETECTION AND CHARACTERIZATION OF ROTA VIRUS**” is the bonafide work done by me at the Department of Microbiology, Government Stanley Medical College and Hospital, Chennai, under the guidance and supervision of **Prof.Dr.R.SELVI, M.D.**, Professor of Microbiology, Government Stanley Medical College, Chennai-600 001.

This dissertation is submitted to The Tamil Nadu Dr. M. G. R. Medical University, Chennai in partial fulfillment of the University regulations for the award of degree of M.D. Branch IV Microbiology examinations to be held in April 2012.

Place : Chennai.

Date :

Signature of the Candidate

(DR. K.SUBHA)

## ACKNOWLEDGEMENT

I humbly submit this work to the **ALMIGHTY** who has given me the health and ability to pass through all the difficulties in the compilation and proclamation of this blue print.

I wish to express my sincere thanks to our Dean i/c, **Dr.R.Selvi M.D.**, for permitting me to use the resources of this institution for my study.

I feel indebted to **Prof Dr. R.Selvi M.D.**, Professor and Head i/c, Department of Microbiology for her unflinching interest, relentless efforts constant encouragement, innovative ideas, excellent guidance, encouragement and freedom given to me throughout this study.

I am extremely thankful to my Assistant Professors **Dr.A.Vasumathi, M.D, Dr.David agatha, M.D., Dr.Eunice swarna jacob, M.D., Dr.shanthi, M.D., Dr.Hema, M.D., and Dr.Pavendan. M.D.**, of Department of Microbiology for their constant support, encouragement, valuable advice and timely help in carrying out this study.

I would like to thank our former Assistant Professors **Dr.Dilli rani M.D., and Dr. Usha krishnan M.D.**, for their valuable assistance in my study.

I extend my thanks to Professor **Dr. Mohamed meeran M.D;** Department of Microbiology, Institute of Child Health and Hospital for Children Chennai.

I am thankful to **Dr.Jeyachandran,M.D;** Director, Institute of Child Health and Hospital for Children, Chennai .

I express my special thanks and gratitude to Prof and HOD **Dr. Nirmala, M.D;** and Prof **Dr.Sumathi,M.D;** Department of Paediatric gastroenterology, Institute of Child Health and Hospital for Children, Chennai.

I owe my special thanks to Deputy Director **Dr.Kaveri, M.D.,** Department of Virology, for providing the technical support and guidance during this study to do Polymerase Chain Reaction at King Institute of Preventive Medicine, Guindy, Chennai.

It is my pleasure to thank **Mr Senthil raja and Mr Suresh babu.,** Department of Virology, King Institute of Preventive Medicine, Guindy, Chennai for their immense support for my study.

I would like to thank all **my colleagues and all staff** of Department of Microbiology and Immunology, Stanley Medical College and Chennai-1 for their help and encouragement.

I acknowledge my thanks to **Mr.Arumugam,** Professor in statistics, Muthu Kumaran Medical College, for his help during my study in statistical analysis.

I would like to thank the **institutional ethical committee,** Stanley Medical College for approving my study.

I also extend my thanks to all the **children,** parents and guardians who participated in my study.

Finally I am indebted to **my parents, friends and family members** who have been solid pillars of everlasting support and encouragement and for their heartfelt blessings.

INSTITUTIONAL ETHICAL COMMITTEE,  
STANLEY MEDICAL COLLEGE, CHENNAI-1

Title of the Work : Study of prevalence of Bacterial, Parasitic and rota viral  
Infections in children less than five years of age with  
Diarrhea

Principal Investigator : Dr.K.Subha

Designation : PG in M.D (Microbiology)


Department : Department of Microbiology  
Government Stanley Medical College,  
Chennai-1

The request for an approval from the Institutional Ethical Committee (IEC) was considered on the IEC meeting held on 01.02.2011 at the Modernized Seminar Hall, Stanley Medical College, Chennai-1 at 2PM

The members of the Committee, the secretary and the Chairman are pleased to approve the proposed work mentioned above, submitted by the principal investigator.

The Principal investigator and their team are directed to adhere to the guidelines given below:

1. You should inform the IEC in case of changes in study procedure, site investigator investigation or guide or any other changes.
2. You should not deviate form the area of the work for which you applied for ethical clearance.
3. You should inform the IEC immediately, in case of any adverse events or serious adverse reaction.
4. You should abide to the rules and regulation of the institution(s).
5. You should complete the work within the specified period and if any extension of time is required, you should apply for permission again and do the work.
6. You should submit the summary of the work to the ethical committee on completion of the work.

 08/11/2011  
MEMBER SECRETARY,  
IEC, SMC, CHENNAI

## **CONTENTS**

<b>SL.NO.</b>	<b>TITLE</b>	<b>PAGE NO.</b>
1.	INTRODUCTION	1
2.	AIMS AND OBJECTIVES	5
3.	REVIEW OF LITERATURE	6
4.	MATERIALS AND METHODS	30
5.	OBSERVATION & RESULTS	46
6.	DISCUSSION	60
7.	SUMMARY	70
8.	CONCLUSION	73
9.	ANNEXURES	
	APPENDIX	
	BIBLIOGRAPHY	
	MASTER CHART	
	KEY TO MASTER CHART	
	PROFORMA	

# *Introduction*



## **INTRODUCTION**

The gastrointestinal tract is home to 10 times more bacteria than cells in the entire human body. It is the site of sophisticated interactions between microbial pathogens, commensals, host epithelial cells and the immune system, a kind of jungle of biologic interactions, evolution and natural history whose balance is crucial for childhood growth and development.<sup>59</sup>

Diarrhoea is one of the most common causes of morbidity and mortality in children worldwide. Globally, there are about two billion cases of diarrhoeal disease every year<sup>106</sup>. Diarrhoeal disease is the second leading cause of death in children under five years of age with an estimated 1.5 million child deaths every year. It kills more young children than AIDS, malaria and measles combined<sup>99</sup>.

Diarrhoeal disease continues to be a public health problem especially in developing countries where they are estimated to be responsible for 2.5 million infant deaths per year with an annual mortality rate of 4.9/ per 1000 children and an incidence of 3.2 episodes of diarrhoea per child-year among children under 5 years of age.<sup>50</sup>

In India, one third of total paediatric admissions in hospitals are due to diarrhoeal diseases and 17% of all deaths in indoor paediatric patients are diarrhoea related<sup>76</sup>. Diarrhoea is the cause of death in almost 23% of Indian children who die before the age of 5.<sup>40</sup>

In developing countries , diarrhoeal disease is most commonly due to infectious cause.<sup>28</sup> Although many number of viral , bacterial and parasitic causes of diarrhoea have been identified todate , only a few of the etiologic agents cause the vast majority of diarrhoeal disease in children in the developing world and include rotavirus, diarrhoeagenic *Escherichia coli*, *Campylobacter jejunii*, *Shigella* sp, nontyphoidal *Salmonella* ,*Giardia lamblia*, *Cryptosporidium* sp and *Entamoeba histolytica*.<sup>91</sup> Many of these organisms are transmitted easily through food or water or from one person to another and some are devastating to individuals with compromised immune system.<sup>78</sup>

Diarrhoeagenic *Escherichia coli* pathotypes represent a leading bacterial cause of paediatric diarrhoea in developing countries. The diarrhoeagenic *Escherichia coli* increasingly being reported in recent years is the Enterohaemorrhagic *E.coli*<sup>38</sup> .The enterohaemorrhagic *E.coli* cause severe disease in humans such as haemolytic uremic syndrome by the production of shiga toxin<sup>16</sup> .

Worldwide the incidence of shigellosis is highest among children 1 to 4 years old<sup>49</sup> . In developing countries, shigella infections most commonly caused by *S.flexneri* are mainly endemics causing approximately 10% of all diarrhoeal episodes among children less than 5 years of age. It is estimated that shigella causes 164.7 million cases of diarrhoea of which 163.2 million occur in developing countries, and 1.1 million deaths each year worldwide mostly in developing countries<sup>6</sup> . Regarding parasitic causes, *Entamoeba histolytica*, *Cryptosporidium*, and *Giardia* are common in developing countries.

Rotavirus disease is the single most important cause of severe gastroenteritis in children throughout the world <sup>3,7,67</sup>. Globally about 30%–40% of hospitalizations and deaths due to diarrhoea among children under 5 years old, and about 5% of all child deaths, are attributed to rotavirus infection<sup>96,26</sup>. It occurs as a sporadic seasonal form, even as severe gastroenteritis of infants and younger children, mostly in the first 2–3 years of life, with a peak at the age of 6–24 months.<sup>26</sup>

Every year, rotavirus gastroenteritis is estimated to cause approximately 527,000(475,000-580,000) deaths globally among children <5 years old<sup>107</sup>. Of about 500,000 annual deaths due to rotavirus worldwide, more than 1,50,000 occur in India<sup>103</sup> and risk of rotavirus disease–associated death by 5 years of age is 1/250 in India<sup>75</sup>.

The burden of this frequent, potentially serious childhood disease in India could be reduced by routine rotavirus vaccination of infants because the efforts to decrease the number of deaths due to diarrhoea by improving water quality and sanitation, promoting breast-feeding, and introducing treatment programs based on oral rehydration therapy have decreased the mortality rate associated with infection due to bacterial and parasitic agents but they have been less effective in reducing rotavirus disease–associated morbidity and mortality<sup>102</sup>.

For rota viral infections, epidemiological studies can be used to select areas for vaccine trials depending upon disease burden and to serve as baselines for identification of new strains should they emerge<sup>72</sup>.The epidemiology of rota virus in India remains in constant flux. So continuous monitoring of rota virus genotype

distribution would be valuable to show up the diversity and changes in the circulating strains.

Since optimal therapy depends on the identity of the infective agent, definitive microbiologic studies are essential<sup>42</sup>. The treatment of bacterial enteric infection depends on the infective agent. For example some organisms such as enterohaemorrhagic E.coli, nontyphoidal Salmonella , antimicrobial therapy is not required as it increase the complication. In contrast, enteric fever and shigellosis benefit from antimicrobial treatment.

Because laboratory tests for faecal specimens are time consuming and expensive, their inclusion in routine patient management usually is limited in nonhospitalized patients to those with severe diarrhoea. Young children are at particular risk of severe diarrhoeal disease and can benefit from appropriate laboratory support<sup>19</sup>. Further, identifying the enteric pathogens that contribute significantly to the causes of diarrhoea in children will help to provide an accurate and region specific estimate of disease burden<sup>91</sup>.

Hence this study was undertaken to identify the bacterial, parasitic profile and rota viral infections in children under 5 years of age with diarrhoea and from children under 5 years of age presenting to hospital for reasons other than diarrhoeal illness.

## *Aims and Objective Of The Study*

## **AIMS AND OBJECTIVES OF THE STUDY**

- To determine the prevalence of bacteria and parasites in stool samples from diarrheal cases of children under 5 years of age.
- To find antibiotic susceptibility of significant bacterial isolates.
- To determine the incidence of rota virus infection in children under 5 years of age with acute diarrhoea.
- To examine the age distribution of rota virus infected children.
- To evaluate clinical severity of rota virus infection in children.
- To evaluate the protective effect of breast feeding on rota virus diarrhoea.
- To evaluate the distribution of different genotypes of rotaviruses circulating in the community.

*Review Of Literature*

## **REVIEW OF LITERATURE**

The term 'diarrhoea' is derived from Greek and it means 'to flow through'. It is defined as a condition characterized by an increase in the frequency, fluidity and weight of the stool, compared to the normal bowel habit of the child. Diarrhoea is usually a symptom of an infection in the intestinal tract, which was described by Hippocrates as 'the abnormal frequency and liquidity of faecal discharge' 2000 years back<sup>84</sup>.

Diarrhoeal diseases are 1.one of the most common illness in infants and young children throughout the world. 2.one of the six leading causes of 10.6 million deaths that occur annually in children younger than 5 years of age 3.Account for 18% of the 10.6 million deaths with the greatest toll being in the developing countries<sup>13</sup>.

Normal defences of the bowel include 1.Gastric acid 2.Bile salts 3.Lymphoid tissue 4.Enterokines 5.Normal bowel flora 6.Secretory immunoglobulin A 7.Motility 8.Hepatic deactivation of toxins.

Diarrhoea may be classified as 'acute' if it lasts for less than 2weeks, 'persistent' if the duration of diarrhoea is 2-4 weeks and 'chronic' if more than 4 weeks duration<sup>86</sup>.



Acute diarrhoea may be due to following reasons<sup>35</sup>:

1. Infectious 90 %
2. Drug induced
3. Ingestion of toxins 10 %
4. Ischemia
5. Other conditions

Infectious diarrhoea may be caused by viruses, bacteria and protozoa. These agents of diarrhoea are acquired by ingestion of contaminated food or water and transmitted by faeco-oral route<sup>97</sup>. Infectious diarrhoea can be classified into 2 distinct clinical syndromes : inflammatory or bloody diarrhoea and noninflammatory or nonbloody diarrhoea<sup>22</sup>. Inflammatory diarrhoeas produce severe form of acute diarrhoea. In contrast, noninflammatory diarrhoeas are milder but produces severe fluid loss with attendant morbidity and mortality<sup>51</sup>.

### **PATHOGENESIS<sup>43</sup>:**

Enteric pathogens adhere to mucosal cells via fimbrial or afimbrial microbial adhesions and induce formation of cuplike pedestals on which bacteria rest. After this interaction, the pathogenesis of the bacteria depends on whether the organism remains adherent to the cell surface and elaborates a secretory toxin, invades the mucosa or penetrates the mucosa.

### Pathogenesis :

Characteristic	noninflammatory [secretory,noninvasive,toxin producing]	inflammatory [mucosal,invasive]	penetrating [systemic]
Mechanism	Activation of adenyl cyclase <sup>34</sup> , Activation of guanylate cyclase, Alteration of intracellular calcium, Stimulation of enteric nervous system, Loss of brush border hydrolase activity, Unopposed crypt cell secretion <sup>20</sup>	Invasion, Cytotoxin	Penetrating
Location <sup>57</sup>	Proximal small bowel	Colon	Distal small bowel
Illness	Watery diarrhoea	Dysentery	Enteric fever
Stool examination	No faecal leucocytes Mild or no ↑lactoferrin	Faecal polymorpho nuclear leukocytes ↑↑lactoferrin	Faecal mononuclear leukocytes
Etiological agents	Vibrio cholerae, Escherichia coli(ETEC*) Clostridium Perfringens Bacillus cereus Staphylococcus aureus Giardia lamblia Rota virus Norwalk like viruses Cryptosporidium parvum E.coli(EPEC,EAggEC)* Microsporidia Cyclospora cayentanensis	Shigella E.coli(EIEC,EHEC)* Salmonella enteritidis Vibrio parahemolyticus Clostridium difficile Campylobacter jejuni Entamoeba histolytica	Salmonella typhi Yersinia enterocolitica

\* ETEC-Enterotoxigenic E.coli, EHEC-Enterohaemorrhagic E.coli,  
EIEC-Enteroinvasive E.coli, EPEC-Enteropathogenic E.col,  
EAggEC-Enter aggregative E.coli

The causes of acute diarrhoea in children are<sup>27</sup>:

Viruses:(70%)	Bacteria:(10-20%)	Parasites
Rota viruses	Enteropathogenic <i>Escherichia coli</i>	Protozoa:
Noroviruses(Norwalk like viruses)	<i>Shigella</i> spp	<i>Cryptosporidium</i>
Enteric adeno viruses	Nontyphoid <i>Salmonella</i> spp	<i>Giardia lamblia</i>
Calciviruses	<i>Campylobacter jejuni</i>	<i>Entamoeba</i>
Astro viruses	<i>Yersinia enterocolitica</i>	<i>histolytica</i>
	Shigatoxin producing <i>E.coli</i>	Helminths:
	<i>Salmonella typhi</i> and <i>Salmonella paratyphi</i>	<i>Strongyloides</i>
	<i>Vibrio cholerae</i>	<i>stercoralis</i>

### **VIRAL GASTRO ENTERITIS:**

Viral gastro enteritis is a global problem in infants and young children<sup>9</sup>. Viruses were long suspected to cause gastro enteritis but efforts to demonstrate specific agents were not successful until the 1970s when the Norwalk agent was first observed by electron microscopy in negatively stained stool suspensions<sup>44</sup>.

Viruses are suspected when vomiting is prominent, the incubation period is longer than 14 hours and the entire illness is over in less than 72 hours. Viral pathogens are likely when there are no warning signs of bacterial infection and there are no epidemiologic clues from the history<sup>22</sup>.

Viruses causing gastroenteritis<sup>10</sup>:

Rota viruses	-	genus Reoviridae
Noro viruses and Sapo viruses	-	genus Calciviridae
Astro viruses	-	genus Astroviridae
Enteric adeno viruses	-	group F of Adenoviridae

Incidence in Children<sup>11,73</sup>:

Rota viruses	30-60%
Noro viruses and Sapo viruses	8-30%
Astro viruses	6-9%
Enteric adeno viruses	3-6%

Other viruses found in the gastro intestinal tract that are not regularly associated with diarrhoea: Enteroviruses, Reoviruses, Toroviruses, Coronaviruses, Parvoviruses. Human immune deficiency virus can infect the gut directly.

Viruses which infect the gut under conditions of immune suppression: Herpes simplex viruses, Cytomegalovirus, Picobirnavirus.

## **ROTA VIRUS:**

### **Introduction:**

Rota viruses are the single most important cause of severe diarrhoeal illness in infants and young children in both developing and developed countries worldwide accounting for 30-50% of these illnesses<sup>74</sup>.

### **History<sup>27</sup>:**

In 1973, Ruth Bishop et al identified round viral particles termed 'rotavirus' by electron microscopy in duodenal biopsies of infants with gastroenteritis in Melbourne. Shortly afterward rotavirus was identified in faeces by electron microscopy by Flewett et al and Bishop et al . Although the human rotaviruses were discovered in 1973, Adams and Kraft described virus like particles in intestinal tissue of mice infected with epizootic diarrhoea of infant mice virus in 1963. These particles were similar to those observed in children by Bishop et al. In 1963, Malherbe et al described the isolation of simian agent 11 virus. In 1967, Malherbe et al described offal agent from intestinal washings of cattle and sheep. In 1969, Mebus et al reported Nebraska calf diarrhoea virus in fetal bovine cell cultures. The murine, simian, offal agent and bovine agents were later found to exhibit characteristic rota virus morphology and to share a group antigen with other rota viruses.

### **Epidemiology:**


Almost all children are infected with rotavirus in early childhood. In developing countries, 65–80% of children have antibodies to rotavirus by 12 months

and 95% have been infected by 24 months. In general, children infected with rotaviruses during the first 3 months of life are asymptomatic, while those infected for the first time after the age of 3 months are usually symptomatic. Because natural infection confers some immunity to disease on subsequent exposures and because this protection increases with each subsequent exposure, the highest rates of rotavirus disease occur between 3 months and 2 years of age<sup>101</sup>. In many developing countries, however, the highest rates of illness occur among children aged 6–11 months. The incidence of rotavirus diarrhoea is similar among children in developed and developing countries. Attempts to control infection by improving water or food are therefore unlikely to alter the incidence of infection<sup>12</sup>. Humans appear to be the main reservoir of rotavirus infections. The exact modes of transmission are unknown but are presumed to involve droplet or direct contact spread via the faecal-oral route.

### **Rotavirus disease burden<sup>104</sup>**

Rotavirus infects nearly every child by the age of 3-5 years. The median age of a primary rotavirus infection is younger in developing countries, ranging from 6 to 9 months (80% occur among infants <1 year old). Developing countries often exhibit one or more periods of more intense rotavirus circulation against a background of year-round rotavirus transmission and a great diversity of rotavirus strains. Every year, rotavirus gastroenteritis is estimated to cause approximately 527,000 (475,000-580,000) deaths globally among children <5 years old. Most of these deaths occur in developing countries and 90% of the rotavirus-associated fatalities occur in Africa and Asia alone. Globally, >2 million children are hospitalized each year for rotavirus infections.

### Structure ,genome and gene protein assignment:



The term 'rota' (latin word ) means a 'wheel'. It is a double stranded RNA virus 65-70 nm in size, resembling little wheels with short spokes radiating from a wide hub to an outer rim.

Rota viruses have a genome of 11 segments of double stranded RNA. The RNA segments code for six structural proteins (VP1,VP2,VP3,VP4,VP7) and six nonstructural proteins(NSP1-NSP6).

The structural proteins make up a triple layered particle and are located in the core (inner layer;VP1-3),inner shell(intermediate layer;VP6) and outer shell (outer

layer;VP4,VP7). The wheel like appearance by electron microscopy of the triple layered particles is diagnostic.

The genome is compromised within the core shell formed by VP2. The transcription complex consisting of VP1 and VP3 is attached at the 12 five fold symmetry positions on the inside of the shell. The addition of VP6 (260 trimers) produces double layered particles, and further addition of VP7 (780 molecules) and VP4 (60 dimers) leads to formation of triple layered particles which are infectious virions after VP4 cleavage<sup>21</sup>.

The triple layered capsid is ordered in five-, three-, and two fold symmetry axes and is perforated by 132 aqueous channels. The class I channels are necessary components to allow transcription in sub viral particles<sup>110</sup>

### **Genes, gene protein assignments, and functions of proteins of group A rota virus<sup>21</sup>**

<b>RNA segment</b>		<b>Protein product</b>			<b>functions</b>
No.	Size (bp)	Description	location	No.of molecules Per virion	
1.	3302	VP1	Inner core	12	RNAdependentRNA polymerase;binds ssRNA;complex with VP3
2	2690	VP2	Core	120	Binds RNA ;required for replicase activity of VP1
3	2591	VP3	Inner core	12	Guanylttransferase,Methyl transferase;complex with VP1



4	2362	VP4	Outer capsid(dimer)	120	Hemagglutinin;cell attachment;neutralization antigen;fusogenic;protease enhanced infectivity
5	1611	NS53,NSP1 (VP5)	Nonstructural	Not applicable	Binds RNA;nonessential for replication
6	1356	VP6	Inner capsid(trimer)	780	Group and subgroup specific antigen;protection(?intracellular neutralization)required for transcription
7	1059	VP9(NSP3)	Nonstructural (dimer)	Not applicable	Binds RNA and eIF-4G1;inhibits host cell translation
8	1104	NS35,NSP2 (VP8)	Nonstructural (octamer)	Not applicable	Binds RNA; NTPase;helicase;involved in +strand RNA packaging
9	1062	VP7	Outercapsid (trimer)	780	Neutralization antigen;binds ca
10	751	VP12(NSP4)	Nonstructural	Not applicable	Intracellularreceptor,viral enterotoxin;protection by specific ab
11	667	VP11(NSP5) NSP6	Nonstructural Nonstructural	Not applicable	Binds RNA ;protein kinase;interacts with NSP2,VP2 AND NSP6 interacts with NSP5

### **CLASSIFICATION<sup>110</sup>:**

1. According to serological cross reactivity of the inner capsid protein VP6,five groups (A-E) have been firmly established, and two more groups (F,G) are likely to exist. Within group A rota viruses, there are subgroups(I;II;I+II;nonI;nonII) according to exclusive reactivities with two VP6 specific monoclonal antibodies.

2. As the two surface proteins (VP4 and VP7) carry neutralization specific antigens, a dual classification scheme has been established. The system differentiates G types (VP7 specific, G for glycoprotein) and P types (VP4 specific, P for protease sensitive protein). So far 14 different G types and more than 20 P types have been detected indicating extensive genomic diversity within group A rotaviruses.

The correlation of G serotypes and their genotypes is practically complete. For many P genotypes, no serotype has yet been established. Thus P serotype and genotype are designated separately but jointly, the latter in square brackets.

As VP4 and VP7 are coded by different RNA segments and as rotaviruses of the same group reassort readily in doubly infected cells, the observed diversity due to combination of VP4 and VP7 is very large.

### **REPLICATION<sup>21</sup>:**

Triple layered rotavirus particles (infectious virions) attach to the surface of the host cell by its outer layer protein VP4 interacting with sialic acid or other receptors. After endocytosis, VP4 and VP7 are removed. The resulting double layered particles are transcriptionally active. The mRNAs are translated into proteins. Rotavirus cores are formed consisting of VP2, VP1 and VP3 into which mRNA molecules are incorporated. Within the core, ssRNA segments are replicated to form dsRNA genome. Rotavirus cores interact with VP6 to form double layered particles (DLPs) which in turn aggregate to form viroplasm. DLPs bud through rough endoplasmic reticulum facilitated by NSP4. In the RER, DLPs acquire VP4 and VP7 to form triple

layered particles(TLPs).The transiently developed envelope is shed before complete maturation. TLPs are released by cell lysis or by non classical vesicular transport.

### **PATHOGENESIS<sup>110</sup>:**

1. Extensive cellular necrosis of the gut epithelium leads to villous atrophy, loss of digestive enzymes, a reduction of absorption and increased osmotic pressure in the gut lumen, resulting in the onset of diarrhoea.
2. This is followed by a reactive crypt cell hyperplasia accompanied by increased fluid secretion.
3. Viral factors: VP4,VP3,VP7 and NSP1,NSP2,NSP4 NSP4 as an enterotoxin increases intracellular calcium concentration disturbing the cellular homeostasis.

### **CLINICAL FEATURES:** Incubation period:1-2 days

Sudden onset of watery diarrhoea lasting 4-7 days,vomiting and rapid dehydration. Rhinorrhoea, congestion of tympanic membrane and pharynx,perianal excoriation may be present. Depending upon the degree of dehydration, lethargy or even shock may be present.

### **NATURAL PROTECTION<sup>17,79</sup>**

Most symptomatic rotavirus infections occur between 3 months and 2 years of age, with a peak incidence between 7 and 15 months. Rotavirus infections are more likely to be severe in children 3 to 24 months of age than in younger infants or older

children and adults . Although children can be infected with rotavirus several times during their lives, initial infection after 3 months of age is most likely to cause severe diarrhoea and dehydration.

### **GEOGRAPHICAL DISTRIBUTION OF ROTAVIRUS:**

Rotavirus infection has been reported throughout the world. Studies between 1986 and 2006 showed that more than 51 rotavirus genotypes were found in Brazil. Approximately 43 of genotype was that of P[8]G1, followed by P[8]G9 and P[4]G2 . In Kenya, the genotype G1 was mainly observed up to the year 2002. Then G9 has emerged as the most predominant genotype and followed by a less frequent genotype G8 .Genotype P[8]G9 was mainly found throughout Latin America. In the United States, the G9 genotype was detected in a 1995–1996 outbreak <sup>82</sup>. In Australia, the overall G9 detection rate increased up to 29 % in 2001<sup>48</sup>. In Japan, G9 was mainly reported in 1998–1999 . In India, G9 strains were detected and were usually found in combination with the P[11] or P[6] genotypes at a detection rate of about 20 % .While genotypes G1P8, G2P4, G3P8, and G4P8 were also seen among Indian children (33 %), strains of P6 (G1P6, G2P6, G3P6, G4P6, and G9P6), which primarily infect asymptomatic newborns but are rare in children with diarrhea were common in India (43 %) <sup>81</sup>. The P[8]G9 was found in New Delhi in late 1998 . In Europe G1–G4 and G9 were the most prevalent genotypes identified: Genotype G1 was identified in Spain, Sweden, and the United Kingdom;G9 in Italy, France,and Belgium; and genotype G4 in Germany. Only the G4 and G9 genotypes<sup>70</sup> were identified in all areas.

## **DIAGNOSIS<sup>58</sup> OF ROTA VIRUS:**

Rotavirus is shed in high concentration in the stool ( $\sim 10^{11}$  particles/ml of faeces) of children with gastroenteritis. Therefore measurement of rotavirus antigen in the stool has been used to identify rotavirus infected patients

### **Rotavirus Detection:**

Techniques for rotavirus detection include:

- Electron microscopy(EM)
- Antigen detection
  1. Enzyme immunoassay (EIA)
  2. Latex agglutination and lateral flow immunoassay (immunochromatography)
  3. Nucleic acid detection (PAGE) and
  4. Nucleic acid amplification (RT-PCR)

### **Electron microscopy**

Electron microscopy is highly specific for detection of rotavirus and is as sensitive as some EIAs. However, the method is too labour intensive for routine detection of rotavirus in large numbers of stool specimens. In addition, EM requires an expensive instrument and highly trained personnel and cannot distinguish between rotaviruses of different groups.

### **Antigen detection**

The most widely used methods for rotavirus diagnosis are based on detection of protein antigens on rotavirus particles in stool specimens. The most appropriate antigen detection format for large-scale surveillance studies is an EIA that uses

rotavirus specific antibodies to capture antigen onto wells of plastic plates. The antigen is then detected in a colorimetric reaction using a second rotavirus-specific antibody coupled to a detector enzyme. The EIA format is highly sensitive and specific and is adaptable to large sample volumes in the 96-well plate format. The optical density (OD) results can be easily recorded with a standard plate reader, permitting analysis of results with standard computer programs.

Latex agglutination, utilizing latex particles coated with anti-rotavirus antibodies can be used as an alternative to EIA and rapid near patient tests using immunochromatographic methods are being used widely in consulting rooms.

### **Nucleic acid detection**

Because of the large quantities of rotavirus present in stool samples from children with gastroenteritis, the viral nucleic acid segments can be visualized directly after extraction from virus particles, by electrophoresis on acrylamide gels, and staining with ethidium bromide or silver nitrate. After electrophoresis, human rotavirus Groups A, B, and C have distinct patterns of gene-segment distribution, designated electropherotypes. The PAGE method has sometimes been used to diagnose Group A rotavirus infections for surveillance studies. However, this method is very labour intensive and time consuming.

A variety of sensitive conventional or real-time reverse-transcription polymerase chain reaction (RT-PCR) methods have been developed based on primers specific for several different rotavirus genes. These methods have been particularly useful in detecting rotavirus in extra-intestinal tissues, in studies of the duration of

viral shedding in stool and the correlation between disease severity and virus load. RT-PCR is also useful for verifying that RNA extracts contain intact rotavirus RNA. However, it is relatively expensive and labour intensive and detects low copy numbers of rotavirus.

### **Rotavirus Characterization:**

#### **Serotyping and subgrouping with monoclonal antibodies:**

Enzyme immunoassays allow determination of rotavirus VP6 subgroup and VP7 serotype using serotype specific monoclonal antibodies. The five most common rotavirus G serotypes (G1, G2, G3, G4, G9) can be assigned a serotype directly from faecal material using several Enzyme Linked Immunosorbent Assay formats incorporating monoclonal antibodies (Mabs) that bind in a serotype-specific manner to the VP7 protein. Similarly, VP6 subgroupings I, II, I & II and non-I, II can be assigned using binding specificity of VP6 Mabs. Studies using serotyping Mabs have typically typed 60%-70% of strains circulating in the community. The method is rapid and inexpensive.

#### **VP7 serotyping:**

A disadvantage of Mab serotyping is that a substantial fraction of the rotaviruses in fecal specimens cannot be serotyped. However, for some collections of rotavirus specimens, a large percentage of samples will need to be analyzed by RT-PCR to determine the genotypes of the strains not typeable with Mabs. Another drawback of Mab serotyping is the need for continual supplies of Mabs and rotavirus hyperimmune antisera, both of which must be produced in animals.

**VP4 serotyping:** Many cross-reactive epitopes observed between different P serotypes/subtypes in rotavirus field isolates precludes the use of this assay for routine P typing studies.

**VP6 subgrouping:**

Polyclonal antibodies to the most abundant virion protein, VP6, are cross-reactive among all human and animal rotaviruses and largely define the group reactivity of rotaviruses. In contrast, some Mabs to the VP6 protein react specifically with different rotavirus strains.

**Polyacrylamide gel electrophoresis (PAGE):**

Rotavirus dsRNA can be detected in clinical specimens by extraction of the viral RNA and analysis by electrophoresis on a polyacrylamide gel followed by silver staining. Rotavirus dsRNA has 11 segments. During electrophoresis through the gel, these negatively charged macromolecules separate according to size. The patterns of dsRNA can be visualized in the gel by staining with silver nitrate. The dsRNA extracted from Group A rotaviruses can be split into four size classes: four large segments, two medium-sized segments, three small segments, and the two smallest segments. Group A human and animal rotaviruses also display two electropherotypes: “long” and “short. Although this relatively time-consuming method requires a trained technologist, the main advantage of PAGE is the lack of ambiguity in the results.

**RNA extraction methods<sup>58</sup>:**

Several methods have been described for the release and/or extraction of rotavirus RNA from clinical specimens. The purpose of these methods is to:



- Disrupt infected cells and microorganisms, resulting in the release of nucleic acids
- Protect the nucleic acids from degradation
- Remove inhibitors of amplification
- Concentrate the target nucleic acid
- Recover the nucleic acid in an environment suitable for its use in the PCR

Method involving crude lysis of microorganisms in specimens containing a high concentration of the target nucleic acid might be suitable for PCR, but additional nucleic acid extraction procedures are typically required to remove inhibitors and concentrate the target nucleic acid. Crude lysis might involve physical methods, such as freeze-thawing or sonication, or chemical methods using detergents, enzymes, or chaotropic agents. Some nucleic acid extraction methods rely on the differential solubilities of nucleic acids and proteins in phenol and water, as in phenol-chloroform extraction methods, or the ability of nucleic acids to bind to silica, as in silica guanidinium isothiocyanate extraction methods. Concentration of extracted nucleic acid is accomplished by precipitation with ethanol.

### **RT-PCR:**

Rotaviruses in clinical specimens can be detected and G and P types determined by extraction of the viral RNA from faecal specimens and analysis by semi-nested RT-PCR with primers specific for regions of the genes encoding the VP7 (G-type) or VP4 (P-type). The objective is to obtain genotype-specific PCR products for analysis on an agarose gel or sequencing gel. RT-PCR of rotavirus dsRNA has three steps: 1) denaturation of dsRNA, 2) reverse transcription of dsRNA, and 3)

amplification of cDNA. PCR consists of these steps: 1) heating the DNA to be amplified to separate the two template strands, 2) adding two primers that are complementary to the region to be amplified, 3) adding a heat-stable DNA polymerase enzyme that catalyses the extension of the primers using the DNA strand as template, and 4) repeating the cycle, with the newly synthesised cDNA heat-denatured and the enzymes extending the primers attached to the liberated single DNA strands.

### **RT-PCR genotyping:**

RT-PCR genotyping methods are used increasingly as a surrogate for serotyping. Since RT-PCR genotyping can determine both G and P types, confirm results, and characterize non-typeable strains with nucleotide sequencing, RT-PCR genotyping is the method of choice for most laboratories.

Rotavirus genotyping methods are based on semi-nested RT-PCR, in which viral RNA extracted from fecal specimens is reverse-transcribed and amplified by PCR in the presence of consensus primers for the rotavirus genes specifying G (gene 9) or P (gene 4) serotype.

The primers are selected to be homologous to strains from different serotypes, so that one primer pair can be used to amplify most human rotavirus strains. The DNAs from the first amplification cycle are used as a template in a second PCR in the presence of one of the original consensus primers and a mixture of genotype-specific primers of opposite polarity from the consensus primer, each designed to yield a product of different size.

**Issues in strain genotyping:**

1. Non typeable (NT) strains resulting from genetic variation in common strains.

2. Non typeable strains resulting from the presence of novel strains..

Examples include the detection of types G5, G6, G10, G12, P[11], and P[14] among NT strains. Although these novel strains have usually been detected at very low frequency, examples of high-incidence detection of such strains have also been reported.

**Other reasons for an inability to type strains:**

False-positive EIA, insufficient or degraded RNA, the presence of residual stool inhibitors in the RNA extract, or technical problems with the assay itself.

**Confirmation of results:**

Although genotyping methods have been shown to be >90% accurate, misidentification by RT-PCR methods does occur. Although several confirmation methods have been described (e.g., Southern hybridization with cDNA and oligonucleotide probes or serotyping methods), sequence analysis has become the standard for both confirmation and identification of NT strains.

**Other characterization methods:**

Additional characterization techniques include cultivation in cell culture to amplify the amount of virus present and dilute out stool inhibitors, followed by repetition of routine methods or sequencing. If the sequences of the VP4 and/or VP7 genes suggest a novel serotype, it might be necessary to prepare hyperimmune sera to

the strains and conduct cross-neutralization tests to determine if the strains are antigenically distinct from known rotavirus serotypes. These types of studies have helped demonstrate that some rare human rotaviruses arose through interspecies transmission of an animal rotavirus to humans. Such studies also suggest that some strains, both common and uncommon, probably arose through reassortment between human and animal rotaviruses. Thus, the analysis of untypeable rotavirus strains from surveillance studies has been important in defining the genetic diversity and possible origin of many human rotaviruses.

### **Rotavirus vaccines:**

#### Currently Licensed Vaccines:

1. Human-Bovine Rotavirus Reassortant Vaccine (RotaTeq)
2. Live-Attenuated Human Rotavirus Vaccine (Rotarix)

Vaccine	Parent strain	genotype Formulation	Dose regimen
RotaTeq	Bovine rotavirus strain WC3, P7[5]G6	5 reassortants; 4 reassortants with the VP7 gene from G1, G2, G3, or G4 and 1 reassortant with the VP4 P1A[8] gene from the human rotavirus parent strain with the remainder of the genes from the WC3 bovine rotavirus Parent strain	3 oral doses at 2, 4, and 6 months of age
Rotarix	Human rotavirus strain 89-12, P1A[8]G1	No reassortants; RIX4414, a further-passaged human rotavirus 89-12 strain	2 oral doses at 2 and 4 months of age

## **BACTERIAL AGENTS:**

### **ESCHERICHIA COLI:**

*Escherichia coli* was first identified by Theodor Escherich, German paediatrician while studying on the intestinal flora of infants. He described the organism in 1885 as *bacterium coli commune* and established its pathogenic properties in extra intestinal infection.

Diarrhoeagenic *E.coli* is classified as<sup>65</sup>

1. Enterotoxigenic *E.coli* (ETEC)
2. Enteropathogenic *E.coli* (EPEC)
3. Enterohaemorrhagic *E.coli* (EHEC)
4. Enteroinvasive *E.coli* (EIEC)
5. Enteroaggregative *E.coli* (EAEC) and
6. Diffusely Adherent *E.coli* (DAEC)

ETEC and EPEC are important causes of diarrhoea in infants and ETEC is a primary cause of traveller's diarrhoea. Diarrhoeagenic *E.coli* can produce watery, cholera like diarrhoea (ETEC), dysentery like symptoms (EIEC), and grossly bloody diarrhoea (EHEC). *E.coli* O157:H7, one of the common EHEC serotypes was first described by Karmali et al in 1982. It produces shiga like toxin and is associated with haemolytic uraemic syndrome, especially in children<sup>77</sup>. The medium of choice for this organism is Sorbitol Mac conkey agar. Other tests for detection are MUG (4 methyl umbelliferyl beta D Glucuronide) test, latex agglutination test and PCR for detecting genes *stx1* and *stx2*<sup>49</sup>.

**SHIGELLA:**

*Shigella dysenteriae*, one of the four species of *Shigella*, first was isolated by Shiga in 1898. There are four species-*S. dysenteriae*, *S. flexneri*, *S. boydii* and *S. sonnei*. *S. flexneri* and *S. dysenteriae* are the predominant species in developing countries. Endemic Shigellosis is typically a paediatric disease with most patients below 5 years of age.

**SALMONELLA:**

Age specific attack rates for *Salmonella* infection are highest in children younger than 4 years of age with higher invasiveness and mortality in infants. Antimicrobial treatment is not indicated for patients with uncomplicated, noninvasive *salmonella* gastroenteritis because therapy may prolong the the duration of carriage.

**VIBRIO CHOLERAЕ:**

*Vibrio cholerae* is most dangerous vital pathogen which has morbidity and mortality rate higher than other organisms.

**PARASITIC AGENTS:**

Regarding parasitic causes, *Entamoeba histolytica* is common in developing countries. *Cryptosporidium* has been documented in atleast of 5% of diarrhoeal stools in developing countries<sup>16</sup>. *Giardia* has bimodal age distribution with children less than 5 years most frequently affected.

## **TREATMENT:**

The broad principles of management of acute gastroenteritis in children include oral rehydration therapy, enteral feeding and diet selection, Zinc supplementation and additional therapies such as probiotics.

## **PREVENTION<sup>66</sup>**

Preventive strategies includes

1. Promotion of exclusive breast feeding
2. Improved complimentary feeding practices like Vitamin A supplementation reduces childhood diarrhoea by 34%.
3. Improved water and sanitary facilities and promotion of personal and domestic hygiene.
4. Behavioural change strategies through hand washing promotion and access to soap reduce the burden of diarrhoea in developing countries.
5. Rotavirus and measles vaccinations.

## *Materials And Methods*



## **MATERIALS AND METHODS**

**TYPE OF STUDY:** Cross sectional study

**PERIOD OF STUDY:** Oct 2011-Nov 2012

**PLACE OF STUDY:**

This study was conducted at the department of Microbiology, Stanley Medical College, Chennai. Samples were collected from Institute of Child health, Egmore Chennai-3 and Institute of social paediatrics, Stanley, Chennai-1 .

### **SELECTION OF STUDY GROUP**

A total of 150 children, 0-5 years of age were included in the study. The patients were clinically examined and selected for the study after obtaining the history.

### **INCLUSION CRITERIA:**

Children less than 5 years of age with complaints of more than 3 episodes of watery stools with or without mucus and blood for a period less than 2 weeks and not on antibiotics or any laxatives were included in the study.

### **EXCLUSION CRITERIA:**

Children above 5 years of age, Children with complaints of diarrhoea more than 2 weeks and children who acquired diarrhoeal illness after hospital admission were excluded from the study.

### **SELECTION OF CONTROL GROUP:**

A total of 50 children aged 5 years or below admitted to the hospital for causes other than diarrhoea were included as controls.

### **ETHICAL CONSIDERATION**

Ethical and research clearance was obtained from the Ethical committee, Stanley Medical College. Permission to conduct the study was sought from the respective hospital authorities. Informed consent was obtained from parents/guardians of the child before enrolment into the study.

### **STATISTICAL ANALYSIS:**

The matching of study and control group was analysed by students 't' test for independent variables and the other variables were analysed by chi square test. The 'z' test of proportions between the groups was performed wherever necessary. The above statistical procedures were performed by the statistical package PASW(Predictive and Analysis Software)statistics -18 so called SPSS. The p values less than 0.05 were considered as significant.

### **COLLECTION AND TRANSPORT OF STOOL SAMPLES:**

The stool samples were collected in a clean wide mouthed sterile container, labelled properly, transported to the laboratory in ice pack and processed within one to two hours.

## **MICROBIOLOGICAL ANALYSIS:**

A portion of each sample was stored in screw capped vials at -70°C for analysis of rota virus.

### **Macroscopic examination:**

The stool samples were examined for colour, consistency, presence of blood, mucus, segments of parasite or worms.

### **Direct microscopic examination:**

Saline and Iodine wet preparations were examined for the presence of erythrocytes, leukocytes, trophozoites, ova and cysts of the parasites.


### **Saline wet mount<sup>41</sup>:**

A minute portion of the faeces is diluted with 0.9% NaCl and a drop of it was placed on a clean glass slide. A 22×22 mm clean coverslip was carefully placed over the suspension avoiding air bubbles.

### **Iodine wet mount<sup>41</sup>:**

A drop of diluted Lugol's iodine is added to the drop of saline emulsion of faeces on a clean glass slide. Cover slip is put on. Both the preparations were observed under low power objective and suspicious object was examined under high power objective.


**Saline mount showing trophozoites of Giardia lamblia**




**Iodine mount showing red blood cells and leukocytes**




**Iodine mount showing red blood cells**




**Iodine mount showing cyst of Entamoeba histolytica**



**Iodine mount showing fertilised egg of Ascaris lumbricoides**



**LPCB mount showing Giardia lamblia**




**Modified Kinyoun's Acid Fast staining method** was used for detecting coccidian parasites in the stool specimen<sup>54</sup>.

1. Heat fixed faecal smear was covered with a strip of a filter paper. The slide was flooded with Kinyoun's carbol fuchsin and allowed to stain for 5 min.
2. The stain was tipped off and filter paper removed. The slide was rinsed briefly(3-5 sec) with 50% ethanol and then thoroughly with water.
3. 1% sulphuric acid was used to decolorize for 2 min or until no more colour ran from the slide. Slide was rinsed in water and drained.
4. Counterstaining was done with methylene blue for 1 min. Slide was rinsed with water and air dried.
5. The slide was examined under oil immersion objective.


### **Culture:**

Samples were cultured on Mac conkey agar, Sorbitol MacConkey agar, Xylose lysine deoxycholate agar and Thiosulphate citrate bile salts sucrose (TCBS) agar and incubated at 37°C overnight. Samples were also inoculated in selenite F broth and alkaline peptone water, incubated for 18 and 4 h, respectively, for enrichment of *Salmonella* and *Vibrio* spp. and subcultured on xylose lysine deoxycholate agar and TCBS agar, respectively. If *Vibrio cholerae* was suspected, motility was observed by hanging drop method. From each sample the lactose positive and lactose negative colonies were subjected to identification procedures. *Shigella*, *Salmonella* and *Vibrio cholerae* isolates were serotyped by slide agglutination test using specific antisera.

**Modified Acid Fast stain showing *Cryptosporidium parvum***



**Modified Acid Fast stain showing pus cells**






**Mac Conkey agar showing lactose fermenting colonies of Enterohaemorrhagic Escherichia coli**




**Sorbitol Mac Conkey agar showing colonies of Enterohaemorrhagic Escherichia coli**






### **XLD plate showing colonies of Escherichia coli**



### **Biochemical reactions of Escherichia coli**



1. TSI-A/A
2. CITRATE-NOT UTILISED
3. INDOLE-POSITIVE
4. GLUCOSE- FERMENTED WITH ACID AND GAS
5. LACTOSE- FERMENTED
6. SUCROSE-NOT FERMENTED
7. MALTOSE-FERMENTED
8. MANNITOL- FERMENTED
9. XYLOSE - FERMENTED
10. ARABINOSE- FERMENTED
11. UREASE NEGATIVE


**Mac Conkey agar showing non lactose fermenting colonies of Shigella**



**XLD plate showing colonies of Shigella**



### **Biochemical reactions of *Shigella flexneri***




1. TSI-K/A
2. CITRATE-NOT UTILISED
3. INDOLE-NEGATIVE
4. GLUCOSE- FERMENTED WITH ACID
5. LACTOSE- NOT FERMENTED
6. SUCROSE-NOT FERMENTED
7. MALTOSE- NOT FERMENTED
8. MANNITOL- FERMENTED
9. UREASE NEGATIVE

### **Slide Agglutination of *Shigella flexneri***



### Biochemical reactions of *Shigella dysenteriae*




1. TSI-K/A
2. CITRATE-NOT UTILISED
3. INDOLE-NEGATIVE
4. GLUCOSE- FERMENTED WITH ACID
5. LACTOSE- NOT FERMENTED
6. SUCROSE-NOT FERMENTED
7. MALTOSE- NOT FERMENTED
8. MANNITOL- NOT FERMENTED
9. UREASE NEGATIVE

**Blood agar plate and TCBS plate showing colonies of *Vibrio cholerae***




**Biochemical reactions of *Vibrio cholerae***




1. TSI-A/A
2. CITRATE- UTILISED
3. INDOLE-POSITIVE
4. GLUCOSE- FERMENTED WITH ACID
5. LACTOSE- NOT FERMENTED
6. SUCROSE- FERMENTED
7. MALTOSE-FERMENTED
8. MANNITOL- FERMENTED
9. ARABINOSE- NOT FERMENTED
10. UREASE NEGATIVE



**Slide Agglutination of Vibrio cholera**



**String test for Vibrio cholerae**



Similar to study group, the stool samples from control children were also processed by standard microbiological procedures.

The following tests were used for identification :

Catalase, Oxidase, Indole, Triple Sugar Iron agar, Citrate, Urease, carbohydrate fermentation tests and motility.


#### **Antimicrobial susceptibility:**

The significant isolates were subsequently tested for antimicrobial susceptibility by Kirby-Bauer disc diffusion method with antibiotics ampicillin 10 µg, cefotaxime 30 µg, ciprofloxacin 5 µg, co-trimoxazole T1.25/S23.75 µg, gentamicin 10 µg, amoxy clavulanic 20/10 µg acid, tetracycline 30 µg and chloramphenicol 30 µg.

Mueller-Hinton agar plate was inoculated with 0.5 McFarland standard inoculums to obtain a lawn culture. Using sterile forceps, discs were placed over the agar surface, incubated at 37°C for overnight. The results were interpreted as per Clinical Laboratory Standards Institute (CLSI) standards.


The *Escherichia coli* strain ATCC 25922 was included as a quality control in all tests.

Antimicrobial susceptibility of *Shigella flexneri*



AMPI- AMPICILLIN, CIP- CIPROFLOXACIN, CEFO- CEFOTAXIME,  
AMX-CLAV- AMOXY CLAVULANIC ACID, GEN- GENTAMYCIN,  
COTRI- COTRIMOXAZOLE

Antimicrobial susceptibility of *Vibrio cholerae*



TET-TETRACYCLINE, CHLO-CHLORAMPHENICOL, PB-POLYMYXIN,  
AMP-AMPICILLIN, COT-COTRIMOXAZOLE



## **DETECTION AND CHARACTERIZATION OF ROTA VIRUS:**

### **Detection of Rota virus:**

Rota virus was identified from all stool samples with commercially available ELISA kit detecting group specific VP6 antigen for rota virus.

1. Antigen detection: was done by Enzyme Linked Immunosorbent assay method (ELISA) according to manufacturer's instruction.[ RIDASCREEN ]

### **Test principle**

This is a sandwich-type of ELISA. Monoclonal antibodies against a capsid protein of gene 6 (VP6) of the rotaviruses are applied to the surface of the well in the microwell plate. This is a group-specific antigen which occurs with all rotaviruses which are pathogenic to humans. A suspension of the stool sample which is to be tested together with other monoclonal anti-rotavirus antibodies, which are conjugated with horseradish peroxidase, is pipetted into the well in the microwell plate for incubation.

## ELISA kit for rota virus antigen detection



## ELISA reader



## ELISA washer



In the presence of rotaviruses, a sandwich complex forms which is made up of the immobilised antibodies, the unattached enzyme-labelled antibodies are removed during a further washing phase. After adding the substrate, the attached enzyme changes the colour of the previously colourless solution in the wells of the microwell plate to blue if the test is positive. On adding the stop reagent, the colour changes from blue to yellow. The extinction is proportional to the concentration of rotavirus antigens present in the sample.

**Preparing the wash buffer:**

1 part wash buffer concentrate was mixed with 9 parts distilled water

**Preparing the samples:**

Approx. 100 µl of sample was suspended in 1 ml sample dilution buffer in a labelled test tube and homogenised by mixing in a vortex mixer. Then centrifuged at 5000 rpm for 5 minutes. The supernatant was used in the test.

**Procedure:**

All reagents were brought to room temperature.

1. 100 µl of sample-dilution buffer (= negative control) was added to well A1 and B1.
2. 100 µl of positive control was added to wells c1 and D1.
3. 100 µl of the stool suspension added in the wells starting from E1.

4. Next, 2 drops (100 µl) of the enzyme-conjugated antibody [Conjugate] was added and, after mixing thoroughly, incubated at room temperature (20 – 25 °C) for 60 minutes.
5. After incubation the wells were washed 5 times using 300 µl wash buffer each time.
6. 2 drops (100 µl) of substrate was added to each well. Then incubated the plate at room temperature (20 - 25 °C) for 15 minutes in the dark.
7. After this, 1 drop (50 µl) stop reagent was added to each well to stop the reaction
8. After mixing carefully (by lightly tapping the side of the plate) absorbance was read at 450 nm using a reference wavelength  $\geq 600$  nm

**Test validity:**

Negative control must be less than or equal to 0.2

Positive control must be more than or equal to 0.8

**Evaluation and interpretation:**

Calculating the cut-off:

$$\text{Cut-off} = \text{extinction for the negative control} + 0.15$$

**Test result:**



Samples are considered **positive** if their extinction is more than 10 % above the calculated cut-off.

Samples are considered **equivocal** and must be repeated if their extinction is within  $\pm$  10 % of the cut-off. If repeating the test with a fresh stool sample again yields a value in the grey range, the sample must be considered negative.

Samples with extinctions more than 10 % below the calculated cut-off must be considered negative.

ELISA positive samples were subjected for characterization by RNA extraction and Reverse transcriptase Polymerase Chain Reaction as standardised by Invitrogen .

**ELISA for rota virus antigen detection**



# Stanley Medical College

Plate Name : ROTAVIRUS

00:04:18

Tech ID : K.SUBHA

Kit.Batch : 17.9.11

Filter : 450/655 nm

Plate Status : OK : MeanBlank = Nil

Cutoff : 0.160

Cutoff Formula: NCT1+0.15

1 2 3 4 5 6 7 8 9 10 11 12

0.010 NCT1	0.007 Neg	0.603 Pos	0.004 Neg								
0.010 NCT1	0.006 Neg	0.005 Neg	0.042 Neg								
2.050 PCT1	0.006 Neg	0.005 Neg	0.005 Neg								
2.110 PCT1	0.005 Neg	0.007 Neg	2.389 Pos								
0.010 Neg	0.152 Neg	0.007 Neg	0.007 Neg								
0.010 Neg	0.009 Neg	2.362 Pos	0.011 Neg								
0.010 Neg	0.006 Neg	0.009 Neg	2.304 Pos								
2.390 Pos	0.004 Neg	0.006 Neg	0.006 Neg								

Validation :

NC  $\leq 0.2$

PC  $\geq 0.8$

# Stanley Medical College

Plate Name :Rota virus

09.10.11 13:38:33

Tech ID :K Subha

Kit.Batch :09-10-11

Filter :450/655 nm

Plate Status :OK : MeanBlank = Nil

CutOff :0.160

Cutoff Formula:Nctl+0.15

1 2 3 4 5 6 7 8 9 10 11 12

1.760 Pctl	0.006 Neg	2.403 Pos									
0.010 Nctl	0.006 Neg	0.051 Neg									
2.320 Pos	0.005 Neg	0.387 Pos									
2.350 Pos	0.008 Neg	0.006 Neg									
0.010 Neg	2.300 Pos	0.007 Neg									
2.330 Pos	0.005 Neg	0.003 Neg									
0.000 Neg	2.277 Pos	-0.002 Neg									
0.000 Neg	0.001 Neg	0.002 Neg									

Validation :  $NC \leq 0.2$

$PC \geq 0.8$



## **RNA EXTRACTION AND REVERSE TRANSCRIPTION:**

RNA extraction was done by QIAmp viral RNA extraction method.

1. 560µl of prepared Buffer AVL containing carrier RNA was pipetted into a 1.5 ml microcentrifuge tube.
2. 140 µl of sample was added to the Buffer AVL in the microcentrifuge tube and mixed by pulse vortexing for 15 s.
3. Incubated at room temperature for 10 min.
4. The tube was centrifuged briefly to remove drops from the inside of the lid.
5. 560µl of ethanol (96-100%) was added to the sample and mixed by pulse vortexing for 15 s. Then centrifuged briefly to remove drops from the inside of the lid.
6. 630 µl of the solution from step 5 was applied to the QIAmp Mini column (in 2 ml collection tube) without wetting the rim. The cap was closed and centrifuged at 8000 rpm for 1 min. The QIAmp mini column was placed into a clean 2 ml collection tube and the tube containing filtrate was discarded.
7. The QIAmp mini column was opened and step 6 was repeated.
8. The QIAmp mini column was opened and 500µl of Buffer AW1 was added. Then the cap was closed and centrifuged at 8000 rpm for 1 min. The QIAmp mini column was placed into a clean 2 ml collection tube and the tube containing filtrate was discarded.
9. The QIAmp mini column was opened and 500µl of Buffer AW2 was added. Then the cap was closed and centrifuged at 14000 rpm for 3 min. The QIAmp mini column was placed into a clean 2 ml collection tube and the tube containing filtrate was discarded. Then centrifuged at full speed for 1 min.
10. The QIAmp mini column was placed in a clean 1.5 ml microcentrifuge tube and the old collection tube with filtrate was discarded. The QIAmp mini

column was opened and 60 $\mu$ l of Buffer AVE was added for elution of RNA. Then the cap was closed and incubated at room temperature for 1 min and centrifuged at 8000 rpm for 1 min.

## Thermo cycler



## Agarose gel electrophoresis



## Gel documentation system



**Denaturation of ds RNA:**

40 µl of extracted nucleic acid was added to 0.2 ml PCR tube and ds RNA was denatured at 97°C for 5 min and chilling the tube on ice for 2 min.

**POLYMERASE CHAIN REACTION:****G Typing PCR (VP7):**

1x mix (Full length gene , 1 st round):

2x buffer(with dNTPs and MgCl <sub>2</sub> )	12.5µl
Primer VP7 F(20pmoles/ µl)	1 µl
Primer VP7 R(20pmoles/ µl)	1 µl
Enzyme mix (Taq polymerase and Reverse transcriptase)	0.5 µl
RNase free water	5 µl

1. prepared 1<sup>st</sup> round PCR mix
2. 25 µl of PCR mix was added to each tube.
3. 5 µl of denatured RNA was added . For negative control RNase free water 5 µl was added.
4. The tubes were transferred to the PCR machine room.
5. Brief spin was done in microcentrifuge
6. The tubes were added to the thermocycler
7. For reverse transcription ,the temperature was set to 50°C for 30 min.

8. For PCR, the following cycling conditions were set.

94 °c	2 min	x1
94 °c	1 min	x35
52 °c	1 min	
72 °c	1 min	
72 °c	7 min	x1
15 °c	hold	

**Genotyping: 2<sup>nd</sup> round multiplex PCR:**

For 1 x:

2x buffer(with dNTPs and Mgcl <sub>2</sub> )	12.5µl
Primer VP7 R(20pmoles/ µl)	1 µl
Primer G1(20pmoles/ µl)	1 µl
Primer G2(20pmoles/ µl)	1 µl
Primer G3(20pmoles/ µl)	1 µl
Primer G4(20pmoles/ µl)	1 µl
Primer G8(20pmoles/ µl)	1 µl
Primer G9(20pmoles/ µl)	1 µl
Primer G10(20pmoles/ µl)	1 µl
Enzyme mix (Taq polymerase and Reverse transcriptase)	1 µl
RNase free water	18.5 µl

1. 2<sup>nd</sup> round PCR mix was prepared.
2. 40 µl of PCR mix was added to each tube.

3. 10  $\mu$ l of 1<sup>st</sup> round product was added. For negative control RNase free water 10  $\mu$ l was added
4. The tubes were transferred to the PCR machine room.
5. Brief spin was done in microcentrifuge
6. The tubes were added to the thermocycler
- 7.. For PCR, the following cycling conditions were set.

94 °c	4 min	x1
94 °c	1 min	x30
42 °c	2 min	
72 °c	1 min	
72 °c	7 min	x1
15 °c	hold	

#### **P Typing PCR (VP4):**

1x mix (Full length gene , 1 st round):

2x buffer(with dNTPs and Mgcl <sub>2</sub> )	12.5 $\mu$ l
Primer Con3 (20pmoles/ $\mu$ l)	1 $\mu$ l
Primer Con2 (20pmoles/ $\mu$ l)	1 $\mu$ l
Enzyme mix (Taq polymerase and Reverse transcriptase)	0.5 $\mu$ l
RNase free water	5 $\mu$ l

1. prepared 1<sup>st</sup> round PCR mix
2. 25  $\mu$ l of PCR mix was added to each tube.

3. 5  $\mu$ l of denatured RNA was added. For negative control RNase free water 5  $\mu$ l was added
4. The tubes were transferred to the PCR machine room.
5. Brief spin was done in microcentrifuge.
6. The tubes were added to the thermocycler.
7. For reverse transcription ,the temperature was set to 50°C for 30 min.
8. For PCR, the following cycling conditions were set.

94 °c	2 min	x1
94 °c	1 min	x35
50 °c	1 min	
72 °c	1 min	
72 °c	7 min	x1
15 °c	hold	

**P Genotyping: 2<sup>nd</sup> round multiplex PCR:**

For 1 x:

2x buffer(with dNTPs and Mgcl <sub>2</sub> )	12.5 $\mu$ l
Primer Con3 (20pmoles/ $\mu$ l)	1 $\mu$ l
Primer P4(20pmoles/ $\mu$ l)	1 $\mu$ l
Primer P6(20pmoles/ $\mu$ l)	1 $\mu$ l
Primer P8(20pmoles/ $\mu$ l)	1 $\mu$ l
Primer P9(20pmoles/ $\mu$ l)	1 $\mu$ l
Primer P10(20pmoles/ $\mu$ l)	1 $\mu$ l
Primer P11(20pmoles/ $\mu$ l)	1 $\mu$ l

Enzyme mix (Taq polymerase and Reverse transcriptase)	1 µl
RNase free water	19.5 µl

1. 2<sup>nd</sup> round PCR mix was prepared.
2. 40 µl of PCR mix was added to each tube.
3. 10 µl of 1<sup>st</sup> round product was added. For negative control RNase free water 10 µl was added
4. The tubes were transferred to the PCR machine room.
5. Brief spin was done in microcentrifuge
6. The tubes were added to the thermocycler
- 7.. For PCR, the following cycling conditions were set.

94 °c	4 min	x1
94 °c	1 min	x30
45 °c	2 min	
72 °c	1 min	
72 °c	7 min	x1
4 °c	hold	

## ANALYSIS BY GEL ELECTROPHORESIS <sup>48</sup>

**Preparation of agarose gel<sup>89</sup>:** 1.To prepare 1% agarose gel 1.5gms agarose powder was mixed with 150ml of electrophoresis buffer, then heated in a microwave oven, mixed well until the agarose was uniformly dissolved. 2.After cooling to about




60°C, ethidium bromide was added to the gel (final concentration 0.5 µg/ml) to facilitate visualization of DNA after electrophoresis. After cooling the solution, it is poured into a casting tray containing a sample comb and allowed to solidify at room temperature. 3. After the gel hardens enough, the gel was mounted in electrophoresis tank. 4. Electrophoresis buffer is poured into the electrophoresis tank so that the gel was completely immersed. 5. The comb was carefully removed. 6. Ethidium Bromide is mutagenic and should be handled with extreme caution. Dispose of the contaminated tip into a dedicated ethidium bromide waste container.

### **Gel electrophoresis:**

1. Electrical leads were connected. As the DNA amplified by PCR was charged negative, it migrates from cathode to anode. 2. 2 µl of 6 x loading buffer was added to each tube containing the PCR reactant and mixed. The mixture was slowly loaded into the slots of the submerged gel using a Micropipette. Marker DNAs of known size was loaded into slots. Constant voltage of 50-150 V was applied to allow the gel run until the Bromophenol Blue have migrated  $\frac{3}{4}$  the length of the gel. All PCR products were analysed in 1% agarose gel, stained with ethidium bromide and observed under UV transilluminator.

### G genotyping



### P genotyping



**G Genotyping: First-amplification consensus primers:**

VP7 F        5' ATG TAT GGT ATT GAA TAT ACC AC 3' product size 881bp  
VP7R        5' AAC TTG CCA CCA TTT TTT CC 3'

**Second amplification Type specific primers :**

G1    5' CAA GTA CTC AAA TCA ATG ATG G 3'        product size 618bp  
G2    5' CAA TGA TAT TAA CAC ATT TTC TGT G 3'    product size 521 bp  
G3    5' ACG AAC TCA ACA CGA GAG G 3'        product size 682 bp  
G4    5' CGT TTC TGG TGA GGA GTT G 3'        product size 452 bp  
G5    5' GTC ACA CCA TTT GTA AAT TCG 3'        product size 754 bp  
G9    5' CTA GAT GTA ACT ACA ACT AC 3'        product size 179 bp  
G10   5' ATG TCA GAC TAC ARA TAC TGG 3'        product size 266 bp

**P Genotyping:**

**First amplification consensus primers:**

con3        5' TGG CTT CGC CAT TTT ATA GAC A3'    product size 876 bp  
con2        5' ATT TCG GAC CAT TTA TAA CC 3'

**Second amplification Type specific primers:**

P[8]        5' TCT ACT GGR TTR CAN TGC 3'        product size 345 bp  
P[4]        5' CTA TTG TTA GAG GTT AGA GTC 3'    product size 483 bp  
P[6]        5' TGT TGA TTA GTT GGA TTC AA 3'        product size 267 bp  
P[9]        5' TGA GAC ATG CAA TTG GAC 3'        product size 391 bp  
P[10]       5' ATC ATA GTT AGT AGT CGG 3'        product size 583 bp  
P[11]       5' GTA AAC ATC CAG AAT GTG 3'        product size 312 bp

## *Observation And Results*

## **OBSERVATION AND RESULTS**

200 stool samples were collected from children less than 5 years of age which include study group of 150 children with diarrhoea and 50 controls without diarrhoea.

Bacterial culture was done for the samples and identified by standard microbiological procedures such as colony morphology and relevant bio-chemical reactions .

Saline wet mount , iodine wet mount and modified acid fast staining were done to identify parasites.

Rota virus antigen detection was done for all samples by ELISA. 24 samples showed positivity. Reverse Transcriptase Polymerase chain Reaction was done for determination of G and P genotype of the rota virus strains.

The results of these tests are as follows:

**TABLE 1: Age distribution among study and control group**

Age (months)	Study		Control	
	No.	%	No.	%
0 to 6	10	6.7	3.0	6.0
7 to 12	76	50.7	23	46
13 to 24	43	28.7	12	24
25 to 60	21	14	12	24
Total	150	100	50	100
Mean age	16.2 ± 11 sd months		18.9±12.2 sd months	
Difference of means	2.7			
‘t’ value	1.456			
Degree of freedom	1.98			
p value	1.47			

Most of the children were in the age group of 7-12 months. The study and control group were similar in age distribution.

**TABLE 2: Gender distribution of study (n=150) and control group (n=50)**

Age (mths)	Study group		Control group		Study group		Control group	
	Male	%	male	%	female	%	female	%
0 to 6	4	2.7	2	4	6	4	1	2
7 to 12	42	28	12	24	34	22.7	11	22
13 to 24	25	16.7	6	12	18	12	6	12
25 to 60	15	10	8	16	6	4	4	8
<b>Total</b>	<b>86</b>	<b>57.3</b>	<b>28</b>	<b>56</b>	<b>64</b>	<b>42.7</b>	<b>22</b>	<b>44</b>
Significance	p>0.05				p>0.05			


The study group and control group were similar in gender distribution. In the study group and control group, the male to female ratio was 1.3 :1.

**TABLE 3: Duration of diarrhoea**


Range	Mean duration
24 hrs to 120 hrs	60.6±30.9 hrs

The mean duration of diarrhoea in study group was 60.6±30.9 hrs.

**Age distribution**



**Gender distribution**





**TABLE 4: Breast feeding status among study and control group**

<b>Breast feeding status</b>	<b>Study group</b>		<b>Control group</b>		<b>Total</b>		<b>Chisquare</b>	<b>degree of freedom</b>	<b>p value</b>
	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>			
Children breast fed	83	55.3	39	78	122	61			
Children not breast fed	67	44.7	11	22	78	39	8.099	1	<0.01


The children in the control group had significant breast feeding status than the study group.

**TABLE 5: Isolates identified from stool samples of study and control group**


	Organism	Study group		Control group		Significance
		No.of org identified	%	No.of org identified	%	
<b>Bacterial isolate</b>	Escherichia coli	127	84.7	38	76	p>0.05
	EHEC(Enterohaemorrhagic E.coli)	4.0	2.7	0	0	-
	Shigella sp	15	10	0	0	-
	Vibrio choleraeO1Eltor	1	0.7	0	0	-
	Salmonella species	2	1	0	0	-
	Klebsiella species	21	14	15	30	p>0.05
	Pseudomonas species	8	5.3	3	6	p>0.05
	Proteus sp	5	3.3	2	4	p>0.05
	Staphylococcus aureus	4	2.7	1	2	p>0.05
	Enterococci	8	5.3	2	4	p>0.05
<b>Parasites</b>	Giardia lamblia	2	1.3	0	0	-
	Cryptosporidium parvum	2	1.3	0	0	-
	Entamoeba histolytica cyst	5	3.3	1	2	P>0.05
	Ascaris lumbricoides	1	0.7	0	0	-
<b>Virus</b>	Rota virus	24	16	0	0	-

Rota virus (16% )were identified significantly in the study group followed by Shigella isolates(10%), EHEC isolates(2.7%), Salmonella isolates (1 %), Vibrio cholerae isolates(0.7% ).

### Distribution of bacterial isolates



### Distribution of parasites and rota virus




**TABLE 6: Antimicrobial susceptibility of isolates of Shigella(n=15), Salmonella (n=2) and Vibrio cholerae (n=1) isolates**


	<b>No. of Shigella isolates sensitive</b>	<b>%</b>	<b>No.of Salmonella isolates sensitive</b>	<b>%</b>	<b>No.of Vibrio isolates sensitive</b>	<b>%</b>
Ampicillin 10 mcg	0	0	1	50	1	100
Cotrimoxazole 1.25/3.75 mcg	0	0	2	100	0	0
Ciprofloxacin 5 mcg	15	100	2	100	-	-
Cefotaxime 30 mcg	9	33.3	2	100	-	-
Gentamycin 10 mcg	15	100	2	100	-	-
Amoxy clav 20/10 mcg	9	33.3	2	100	-	-
Chloramphenicol 30 mcg	-	-	-	-	1	100
Tetracycline 30 mcg	-	-	-	-	1	100

All the Shigella isolates were sensitive to ciprofloxacin, gentamycin and none of them sensitive to ampicillin and cotrimoxazole. All the Salmonella isolates were sensitive to ciprofloxacin, gentamycin, cefotaxime, amoxy clavulanic acid and cotrimoxazole. Vibrio cholerae was sensitive to Ampicillin, Chloramphenicol, tetracycline and resistant to cotrimoxazole.

### Anti microbial susceptibility of Shigella and Salmonella isolates



### Antimicrobial susceptibility of Vibrio isolate



**TABLE 7: Breast feeding status among rota virus positive patients and non rota virus patients**

<b>Breast feeding status</b>	<b>Rotavirus patients</b>		<b>Non rotavirus patients</b>		<b>p value</b>	<b>deg of freedom</b>	<b>Chisquare</b>
	<b>No.</b>	<b>%</b>	<b>No.</b>	<b>%</b>			
children breast fed	11	45.8	72	57.1	>0.05	1	1.043
children not breast fed	13	54.2	54	42.9			

Breast feeding status was found in 45.8% of rota virus patients and 57.1% of non rotavirus patients.

**TABLE 8: Selected clinical data of the most important etiological agents**


<b>Organism</b>	<b>No. of patients</b>	<b>No. of patients with</b>				
		<b>watery diarrhoea</b>	<b>bloody diarrhoea</b>	<b>Fever</b>	<b>abdominal pain</b>	<b>vomiting</b>
Rota virus	24	24	0	16	0	20
Shigella spp	15	10	10	11	09	05
Salmonella spp	2	2	1	2	2	1
Vibrio cholerae	1	1	0	0	0	1
Giardia lamblia	2	2	0	0	2	0
Cryptosporidium parvum	2	2	0	0	2	0

Rota virus and Vibrio cholerae infected patients presented as watery diarrhoea associated with vomiting. Shigella and Salmonella infected patients presented as bloody diarrhoea associated with abdominal pain and fever. Cryptosporidium and Giardia infected patients presented as watery diarrhoea and abdominal pain.

**TABLE 9:****Correlation of clinical severity in rota virus and non rota virus patients**

Clinical symptom	Rotavirus diarrhoea patients(n=24)		Non rota diarrhoea patients(n=126)		p value
	No.	%	No.	%	
Fever	16	66.7	77	61.1	p>0.05
≥6 watery stools per day	17	70.8	50	39.7	p<0.01
Vomiting	20	83.3	67	53.2	p<0.001
vomiting ≥4 times per 24 hrs	11	45.8	27	21.4	p<0.05
bloody stools	0	0	20	15.9	-

A significantly higher proportion of rota virus patients than non rota virus patients were associated with more than 6 watery stools per day(70.8% ) and increased bouts of vomiting (45.8%).





**TABLE 10: Distribution of severe dehydration by age group among rota virus and non rota virus diarrhoea patients**


<b>Age group (mths)</b>	<b>Rotavirus diarrhoea(n=24)</b>	<b>%</b>	<b>Non rotavirus diarrhoea(n=126)</b>	<b>%</b>	<b>p value</b>
0-6	0	0	1	0.8	-
7-12	4	16.7	12	9.5	p>0.05
13-24	3	12.5	3	2.4	p>0.05
25-60	0	0	2	1.6	-
Total	7	29.2	18	14.3	p>0.05

29.2% of rota virus patients were associated with severe dehydration out of which most of them were in 7-12 months age group.

**TABLE 11: Age wise analysis of group A rota virus infection among children 0-5 years with diarrhoea**

Age in mths	Rotavirus patients(n=24)		Non rotavirus patients(n=126)		p value
	No.	%	No.	%	
0-6	2	8.3	8	6.3	p>0.05
7-12	17	70.8	59	46.8	p<0.05
13-24	4	16.7	37	29.4	p>0.05
25-60	1	4.2	22	17.5	p<0.05

Overall rota virus infection rate of 16% was found among children with acute diarrhoea. Rota virus positive children were significantly higher in the age group 7-12 months and significantly lesser in the age group 25-60 months.



**TABLE 12: Gender wise analysis of rota virus patients and non rota virus patients**

	male(n=86)		female(64)		p value
	No.	%	No.	%	
Rotavirus patients(n=24)	15	17.4	9.0	14.1	p>0.05
Non rotavirus patients(n=126)	71	82.6	55	85.9	

The incidence of rota virus was 17.4% in male children and 14.1% in female children.

**TABLE 13: Group A rota virus types detected by RT-PCR(n=12)**

No of strains typed by RT-PCR	12	100%
No of strains fully typed	8	66.7%
No of strains partially typed	1	8.3%
No of strains untypeable	3	25%

Out of 24 rota virus strains ,12 were subjected to typing by RT PCR. Out of 12 strains ,66.67% were fully typed for G and P genotype,8.33% were partially typed and 25% were not typeable.

**TABLE 14: Distribution of typed and untyped rota virus strains**

	<b>G type</b>	<b>P type</b>	<b>Total strains</b>
Typeable	9(75%)	8(66.7)	12(100%)
Nontypeable	3(25%)	4(33.3)	12(100%)


Out of 12 rota virus strains, 75% of G genotype and 66.7% of P genotype could be determined. 25% of G genotype and 33.3% of P genotype could not be determined.

**TABLE 15: Distribution of G and P genotype of group A rota virus detected among under five children with diarrhoea**


	<b>Genotype</b>	<b>No of strains</b>	<b>%</b>
G type(n=9)	G1	6	66.7
	G2	2	22.2
	G10	1	11.1
P type(n=8)	P[8]	6	75
	P[4]	2	25

The G1 genotype was identified in 66.7% of rota virus strains, followed by G2 in 22.2% and G10 in 11.1%. P[8] was identified in 75% of the strains and P[4] in 25% of the strains.


### Distribution of typeable strains of rota virus



**Distribution of G types of rota virus**




**Distribution of P types of rota virus**



**TABLE 16: Distribution of G and P type combination of group A rota virus strains detected among under five children with diarrhoea**

<b>GP type</b>	<b>No of strains</b>	<b>%</b>
G1P[8]	6	50
G2P[4]	2	25
G10P [untypeable]	1	25
Total	9	100

G1P[8] was determined in 50% of the strains, followed by G2P[4] in 25% and G10P[untypeable] in 25% of the strains.



*Discussion*



## **DISCUSSION**

Acute infectious diarrhoea is one of the major causes of mortality in children, particularly in developing countries like India. Children under 3 years of age may experience as many as 10 episodes of diarrhoea per year<sup>47</sup>. Rotavirus is among the most common causes of diarrhoea worldwide<sup>18,47</sup> accounting for 134 million episodes/year<sup>47,92,93</sup>.

Effective control of rota viral disease in any community depends upon an accurate understanding of disease burden and knowledge of the relative importance of circulating serotypes. This study was conducted to determine bacterial, parasitic profile and rotavirus detection and characterization of rota virus in children under 5 years of age with acute diarrhoea.

In the present study, the study and control group were similar in age distribution. Most of the children in the study group(50.7%) were in the age group of 7-12 months..(Table 1). This correlates with John Albert, M. et al<sup>39</sup> study in which 58.5% of diarrhoeal patients were in the age group 0-12 months.

In the present study, the study group and control group were similar in gender distribution. In the study group and control group, the male to female ratio was 1.3:1. (Table 2) Thus both the study and control groups were comparable. The present study is in accordance with the study conducted by Mohammad Youssef et al<sup>60</sup> study in which male and female ratio was 1.3:1 and in John Albert, M. et al<sup>39</sup> study ,the ratio was 1:0.7.

In the study group, the mean duration of diarrhoea was  $60.6 \pm 30.9$  hrs. (Table 3). This study correlates with study by Nakawesi et al<sup>64</sup> in which the mean duration of diarrhoea was 90 hrs.

In this study 55.3% and 78% of children were breast fed in study and control group respectively. (Table 4). Since the breast feeding rate was low in study group, they were more prone to infection and diarrhoea.

In the present study, Rota virus was detected in 16% of the study group. The true incidence of rota virus could be higher than 16% as this data represents only children with diarrhoea requiring medical attention.

Distribution of rota virus in different studies:

<b>Study</b>	<b>%</b>
Present study	16
P.Saravanan et al <sup>72</sup>	22.5
S. S. R. Ajjampur et al <sup>91</sup>	25.3
Gagandeep Kang et al <sup>30</sup> study	33

Rota virus was not detected from any one of the control group. This implies that rota virus was significantly associated with diarrhoea.(Table 7). This correlates with the study of M.Aminu et al<sup>55</sup> in which rota virus was not detected in controls.

### Distribution of bacterial pathogens in different studies

<b>Study</b>	<b>Organism</b>	<b>%</b>
Present study	Shigella spp	10
John Albert et al <sup>39</sup>	Shigella spp	9.2
Gopinath Balakrish Nair et al <sup>32</sup>	Shigella spp	7.9
Present study	Vibrio cholerae	0.7
S. S. R. Ajampur et al <sup>91</sup>	Vibrio cholerae	0.6
Present study	Salmonella spp	1
Iruka N et al <sup>36</sup>	Salmonella spp	0.9
Present study	EHEC	2.7
Patrick et al <sup>77a</sup>	EHEC	1.4

The detection of EHEC would avoid unnecessary diagnostic imagings and surgeries on patients infected with EHEC in search of cause of bloody diarrhoea. Also it avoids deleterious antimicrobial and antimotility treatment. Because quinolones which are prescribed for majority of patients are potent inducers of shiga toxin encoding bacteriophages and toxin production in EHEC, early detection helps in identification and monitoring of patients at risk of progression to haemolytic uraemic syndrome.

The above mentioned pathogens were obtained only from study group and none of these isolates from control group. The bacterial pathogens Shigella spp and Salmonella spp were confined mainly to the study group. This correlates with the

study by T.I.Ogunsanya et al<sup>95</sup> in which *Shigella* spp and *Salmonella* spp.were confined mainly to the diarrhoeal group.

Distribution of parasites in different studies:

Study	Organism	%
Present study	<i>Giardia lamblia</i>	1.3
S. S. R. Ajjampur et al <sup>91</sup>	<i>Giardia lamblia</i>	0.63
Present study	<i>Cryptosporidium parvum</i>	1.3
S Das et al <sup>90</sup>	<i>Cryptosporidium parvum</i>	1.4
Mohammad Youssef et al <sup>60</sup>	<i>Cryptosporidium parvum</i>	1.5
Present study	<i>Entamoeba histolytica</i>	3.3
S. Das et al <sup>90</sup>	<i>Entamoeba histolytica</i>	4.8

*Giardia lamblia* and *Cryptosporidium* were not identified in controls thus significantly associated with diarrhoea. This correlates with the study by S. S. R. Ajjampur et al<sup>91</sup> in which *Giardia* and *Cryptosporidium* were not identified in controls.

Antimicrobial sensitivity of significant isolates in different studies:

Study	Isolate	Sensitivity pattern
Present study	<i>Shigella</i>	100% sensitive to ciprofloxacin and gentamycin and 0% sensitive to ampicillin and cotrimoxazole

Roger L.Shapiro et al <sup>85</sup>	Shigella	100% sensitive to ciprofloxacin and gentamycin and 0% sensitive to ampicillin and cotrimoxazole
S.Das et al <sup>90</sup>	Shigella	100% sensitive to ciprofloxacin and gentamycin and 0% sensitive to cotrimoxazole
Present study	Salmonella	100% were sensitive to ciprofloxacin, gentamycin, cefotaxime, cotrimoxazole, amoxy clavulanic acid
Moyo et al <sup>62</sup>	Salmonella	all the isolates(100%) were sensitive to ciprofloxacin, cefotaxime
Present study	Vibrio cholerae	sensitive to ampicillin, chloramphenicol, tetracycline and resistant to cotrimoxazole
Roger L.Shapiro et al <sup>85</sup>	Vibrio cholerae	98% sensitive to tetracycline, 93% to ampicillin 100% resistant to cotrimoxazole.

In the present study, most of the bacterial pathogens showed high rate of resistance to ampicillin and cotrimoxazole which are used for empirical treatment and are readily available over the counter. The high rate of resistance to these antibiotics may be because of their indiscriminate use. Hence periodic monitoring of drug susceptibility and local information of drug resistance is mandatory for providing treatment guidelines for diarrhoea.

In the present study, breast feeding status was found in 45.8% of rota virus patients and did not demonstrate the protective effect of breast feeding against rotavirus diarrhoea.(Table 7). This is in accordance with the study by Wobudeya et

al<sup>108</sup> and Nakawesi et al<sup>64</sup> and Linhares et al<sup>52</sup> in which they have found no evidence of protection of breast feeding against rotavirus diarrhoea .

Since most of the children in the study were above six months of age and on complimentary feeding, the contribution of breast feeding could not be determined

According to Ebina<sup>24a</sup> et al, the intestinal mucosa needs continuous bathing with antibodies and other anti infective components in breast milk for protection against rota virus. So breast feeding may be protective only if it is practised with intensity and frequency that allows continuous high protection of the mucosa rather than the sporadic small volumes.

In our study, Shigella infected patients presented as bloody diarrhoea(66.7%)and fever(73.3%).(Table 8).This is in accordance with the study by Mohammad Youssef et al<sup>60</sup> in which 60% of Shigella infected patients presented as bloody diarrhoea and fever.

Rota virus infected patients presented as watery diarrhoea associated with vomiting. A significantly higher proportion of rota virus patients than non rota virus patients were associated with more than 6 watery stools per day(70.8% ) and increased bouts of vomiting (45.8%). (Table 9). This study correlates with the study of Khitam Muhsen et al<sup>46</sup> in which rota virus infected children significantly presented with more watery stools (87.1%) and more vomiting(57.6%). This shows that rota virus is associated with more severe illness than other enteropathogens.

In the present study, 29.2% of rota virus patients were associated with severe dehydration out of which most of them were in 7-12 months age group.(Table 10). This correlates with the study by A.K. Siddique et al<sup>1</sup> in 16% of rotavirus patients presented with severe dehydration and most of them were in 6-11 months age group. This shows that children in 7-12 months of age group are at higher risk of death due to severe dehydration associated with rota virus infection.

In the present study, rota virus positive children were significantly higher in the age group 7-12 months and significantly lesser in the age group 25-60 months.(Table 11). The present study correlates with the study of P.Saravanan et al<sup>72</sup> , M.John Albert et al<sup>39</sup> study and A.K.Siddique et al<sup>1</sup> in which majority of rota virus positive patients were in the age group 7-12 months.

This could be because of protective effect of maternal antibodies in infants<6 months of age and by the development of natural immunity after successive infections in children >2 years of age. This also indicates that prophylactic measures such as vaccination should be taken in the first few months of life to prevent rota viral infection.

The incidence of rota virus was 17.4% in male children and 14.1% in female children and the incidence rate was similar in both male and female children.(Table 12) This correlates with the study of P.Saravanan et al<sup>72</sup> in India in which no association was found between male(23.9%) and female(21.1%). Another study by R.N kalaf and K.S Ghenghesh<sup>80</sup> showed similar rates among male and female patients,33.6%(40/119) and 32.1%(26/81). Male and female ratio among rota virus

positive patients was 1.2:1 in the present study. This correlates with Alicia Sa'nchez-Fauquier et al<sup>5</sup> study which showed male:female ratio of 1.3:1.

In the present study, 66.7% were fully typed for G and P genotype, 8.3% were partially typed and 25% were not typeable (Table 13). This was similar to Vivek Jain et al<sup>103</sup> study which has showed 12% of partially or nontypeable strains in India. Moyo et al study<sup>61b</sup> showed 6.1% of nontypeable strains and 6% of partially typeable strains in Tanzania.

In the present study, 75% of G genotype and 66.67% of P genotype could be determined. 25% of G genotype and 33.33% of P genotype could not be determined (Table 14). This correlates with the review study of N.A. Cunliffe et al<sup>63</sup> in which 26% of G genotype and 32% of P genotype could not be typeable. In a review study by Ali M. Kheyami et al<sup>4</sup>, 11-31.3% of rota virus strains could not be typeable for G type. In a study by Zuccotti et al<sup>109</sup>, 19.8% of rota virus strains could not be typeable for P type.

The nontypeability of strains may be due to the emergence of new strains. Since rotaviruses genetically mutate, it is to be expected that sometimes RT-PCR methodologies are unable to identify all types. Another reason is that the strain untypeable could be unrecognised which needs further investigation as stated by M. Aminu et al<sup>55</sup>.

In the present study, G1 genotype was identified in 66.7% of rota virus strains being the most predominant type followed by G2 in 22.2% and G10 in 11.1%. (Table



15). This correlates with the study of Malek MA et al<sup>56</sup> in which G1 was the predominant type (80%). Ryuichi Uchida et al<sup>88</sup> study showed predominance of G1 type (77%) among children with rotavirus diarrhoea. Also studies done by Alicia Sa´nchez-Fauquier et al<sup>5</sup>, Zuccotti et al<sup>109</sup>, Nishio O et al<sup>68</sup>, Aminu.M et al<sup>55</sup>, Ali M.Kheyami et al<sup>4</sup>, N.A.Cunliffe et al<sup>63</sup> showed predominance of G1 type in rota virus strains.

Other than the globally common genotypes G1 and G2, G10 genotype was also seen in the present study. G10 genotype has been reported in the study by Gagandeep Kang et al<sup>30</sup> in children with diarrhoea in south India. But previous studies by Dunn et al<sup>23</sup> and Sukumaran M et al<sup>94</sup> have reported G10 type in asymptomatic newborn infants. This implies that G10 genotype is increasingly being associated with symptomatic diarrhoea. G10 has also been reported in the study by Zuccotti et al<sup>109</sup>.

In the present study, P[8] was the predominant P type (75% ) followed by P[4] 25%. (Table 15) .This correlates with the study by Buesa J et al<sup>14</sup>(77.1% of P[8]) and Zuccotti et al<sup>109</sup> in which only p[8] and p[4] types were seen with predominance of p[8]. The studies by Ryuichi Uchida et al<sup>88</sup>, Malek MA et al<sup>56</sup> and Moyo et al<sup>61b</sup> showed predominance of P[8] type of about 80-100%.

In the present study, G1P[8] was determined as the most common combination of G and P type( 50% ), followed by G2P[4] and G10P[untypeable].(Table16). G1P[8] and G2P[4] have been described as globally common genotypes in a review study done by Gentsch et al<sup>31</sup>. This study correlates with Khitam Muhsen et al<sup>46</sup> study which has

shown 49.1% of G1P[8] combination and Buesa J et al<sup>14</sup> study in which 42.7% of G1P[8] combination was found and Foster et al<sup>29</sup> study has shown 40.3% of G1P[8] combination. Ryuichi Uchida et al<sup>88</sup> study have also reported predominance of G1P[8] combination(70%).

*Summary*

## **SUMMARY**

Stool samples were collected from 150 children with diarrhoea and 50 children without diarrhoea. The samples were subjected to saline wet mount, iodine mount, modified acid fast staining and culture. The isolates were identified by gram staining and biochemical reactions. Rota virus antigen was detected in the samples by VP6 specific monoclonal antibodies in Antigen capture Enzyme Linked Immunosorbent Assay. The samples which were positive for rota virus were subjected to Reverse Transcriptase Polymerase Chain Reaction for characterization of the rota virus strains.

In the present study, both the study and control groups were comparable. Diarrhoea was common in the age group of 7-12 months of age followed by 13-24 months.

The children in the study group had breast feeding status significantly lesser than the control group.

Among the bacterial isolates, *Shigella* sp, *Vibrio* sp, *Salmonella* sp and EHEC were seen significantly in the study group children with diarrhoea. All of the *Shigella* and *Salmonella* isolates were sensitive to ciprofloxacin, gentamycin and none of the isolates were sensitive to ampicillin, cotrimoxazole.

*Vibrio* isolates were sensitive to ampicillin, chloramphenicol, tetracycline and resistant to cotrimoxazole.

Among the parasites, *Giardia lamblia* and *Cryptosporidium* oocysts were significantly observed only in the study group.

Rota virus incidence was found to be 16% and it was significantly associated with diarrhoea.

This study could not demonstrate the protective effect of breast feeding against rotavirus diarrhoea as most of the children were above six months of age.

The main clinical presentation of rota virus infected patients was watery diarrhoea associated with vomiting and fever.

When compared with non rotavirus patients, rota virus patients presented significantly with more than 6 watery stools, with frequent episodes of vomiting .

Rota virus patients were associated with severe dehydration out of which most of them were in 7-12 months age group.

Major proportion of the rota virus positive cases fell significantly in the age group between 7-12 months and no significant association was found in gender distribution.

66.7% of the rotavirus strains were fully typed for G and P genotype, 8.3% were partially typed and 25% were not typeable.

75% of G genotype and 66.7% of P genotype could be determined.

G1 genotype was identified as the most predominant type followed by G2.

Along with the globally common genotypes G1 and G2, G10 genotype was also seen.

P[8] was the predominant P type identified followed by P[4] .

G1P[8] was determined as the most common combination of G and P type followed by G2P[4] and G10P[untypeable].

*Conclusion*

## **CONCLUSION**

In the present study, rota virus, *Shigella* sp, *Vibrio* sp, *Salmonella* sp, EHEC, *Giardia lamblia* and *Cryptosporidium* were seen significantly in children with diarrhoea. All of the *Shigella* and *Salmonella* isolates were sensitive to ciprofloxacin and gentamycin. *Vibrio cholerae* was sensitive to tetracycline which is used for chemoprophylaxis and thus holds good still now. High rate of resistance of bacterial isolates to cotrimoxazole and ampicillin was seen which recommends continuous antibiotic surveillance to monitor development of resistance.

Rota virus incidence was found to be 16% among children under five years of age with diarrhoea. Majority of them were in the age group of 7 to 12 months associated with severe dehydration and protective effect of breast feeding was not found against rota virus infection in this age group. The genotype combination of rota virus identified were G1P[8], G2P[4] and G10P[untypeable]. Thus the present study shows significant association of rota virus in children under five years of age with acute diarrhoea and the prevalence of uncommon genotype G10.

The significant association of rota virus in childhood diarrhoea along with clinical severity suggests consideration of a rota virus vaccine in the childhood immunization program. In developing countries like India, exposure to an environment contaminated with human and animal faeces and close contact with animals in the domestic environment are factors enabling viral reassortment and the emergence of new strains.



Most of the rota virus strains in circulation appear to be like those of common genotypes G1-4 which are components of current vaccine. But the non typeable strains pose an unknown antigenic challenge to the current vaccine Rotateq. Hence continuous and prospective monitoring of circulating strains in a large scale study will detect any change in the distribution of rotavirus strains which would influence the vaccine based preventive strategies in India.

*Appendix*

## **APPENDIX I**

### **1. Saline(0.9%Nacl):**

Nacl	0.9g
Distilled water	100ml

Dissolve the Nacl in distilled water.sterilize by autoclaving.

### **2. Iodine solution;**

Lugol's iodine diluted 5 times with distilled water.

Lugol's iodine:

Iodine crystals	5g
Potassium iodide	10g
Distilled water	100ml

Potassium iodide is dissolved in distilled water and iodine crystals are added slowly.The solution is filtered and kept in stoppered bottle of amber colour.

### **3. Kinyoun's Modified Acid Fast Staining:**

Reagents:

#### **1. 50% ethanol**

Add 50 ml of absolute ethanol to 50 ml distilled water.

#### **2. Kinyoun's carbol fuchsin**

Dissolve 4 g of basic fuchsin in 20 ml of 95% ethanol(solution A)

Dissolve 8 g of phenol crystals in 100 ml of distilled water.( solutionB)

Mix solution A and B.

#### **3. 1% sulphuric acid**

Add 1 ml of conc.sulphuric acid to 99 ml of distilled water.

#### **4. Loeffler's alkaline methylene blue**

Dissolve 0.3 g of methylene blue in 30 ml of 95% ethanol.

Add 100 ml of dilute(0.01%)potassium hydroxide.

## **APPENDIX II**

### **1. Mac Conkey agar**

Peptone	20g
Sodium taurocholate	5g
Agar	20g
Neutral red solution,	2% in 50% ethanol 3.5g
Lactose,	10 % aqueous solution 100ml

Dissolve the peptone and taurocholate in the water by heating. Add the agar and dissolve it in the steamer or autoclave. If necessary, clear by filtration. Adjust the pH 7.5.

### **2. Xylose lysine deoxycholate agar**

Yeast extract	3g
Xylose	3.75g
Lactose	7.5g
Sucrose	7.5g
L-Lysine	5.0g
Sodium Chloride	5.0g
Sodium deoxycholate	2.5g
Sodium thiosulphate	6.8g
Ferric ammonium citrate	0.8g
Phenol red	0.08g
Agar	15 g
Water	1 Litre

Except for the deoxycholate, thiosulphate and ferric ammonium citrate, dissolve the ingredients in the water by autoclaving. Cool to 50°C and add 20ml of a solution of sodium thiosulphate 34% and ferric ammonium citrate 4%, and 25 ml of a solution of sodium deoxycholate 10 %. Adjust the pH to 7.4.

### **3.Thiosulphate citrate bilesalt sucrose Agar:**

Composition	grams/litre
Proteose peptone	10.0
Yeast extract	5
Sodium thiosulphate	10
Sodium citrate	10
Oxgall	8
Sucrose	20
Sodium chloride	10
Ferric citrate	1
Bromothymol blue	0.04
Thymol blue	0.04
Agar	15

Final pH 8.6±0.2

Dissolve 89 gms in 1000 ml distilled water, heat to boiling to dissolve the medium completely. after cooling to 50°C, pour into petriplates.

#### **4.Selenite F broth**

Sodium hydrogen selenite	4 g
Peptone	5 g
Lactose	4 g
Disodium hydrogen phosphate	9.5 g
Sodium dihydrogen phosphate	0.5 g
Sterile water	1 litre

All the ingredients were dissolved in sterile water with sterile precautions.

The yellow solution in about 10ml amounts distributed into screw capped universal bottles. Steamed for 20 minutes at 100°C. Adjust pH to 7.1.

#### **5.Mueller- Hinton Agar:**

Beef extract	20 gm
Acidicase peptone	7.5 gm
Starch	1.5 gm
Agar	17 gm
Distilled water	1000 ml

The ingredients were dissolved in one liter of distilled water, mixed thoroughly. Heated with frequent agitation and boiled for 1 minute. pH adjusted to 7.4. Sterilized by autoclaving and poured in plates.

### IDENTIFICATION OF THE ORGANISM :-

Organism	TSI	Citrate	Indole	Oxidase	Catalase	Glucose	Lactose	Sucrose	Maltose	Mannitol	xylose	arabinose	urease	Motility
<i>Escherichia coli</i>	A/A	Not utilised	+	-	+	AG	A	-	A	A	A	A	-	+
<i>Shigella dysenteriae</i>	K/A	Not utilised	-	-	+	A	-	-	-	-			-	-
<i>Shigella flexneri</i>	K/A	Not utilised	-	-	+	A	-	-	-	A			-	-
<i>Shigella boydii</i>	K/A	Not utilised	-	-	+	A	-	-	-	A			-	-
<i>Shigella sonnei</i>	K/A	Not utilised	-	-	+	A	Late	-	-	A			-	-
<i>Salmonella typhi</i>	K/A	Not utilised	-	-	+	A	-	-	A	A	A	-	-	+
<i>Salmonella paratyphi A</i>	K/A	Not utilised	-	-	+	AG	-	-	A	A	-	A	-	+
<i>Salmonella paratyphi B</i>	K/A	utilised	-	-	+	AG	-	-	A	A	A	A	-	+
<i>Salmonella typhimurium</i>	K/A	utilised	-	-	+	AG	-	-	A	A	A	A	-	+
<i>Vibrio cholerae</i>	A/A	utilised	+	+	+	A	-	A	A	A		-	-	+
<i>Klebsiella Pneumoniae</i>	A/A	Utilised	-	-	+	AG	A	A	A	A	+	+	+	-
<i>Klebsiella oxytoca</i>	A/A	Utilised	+	-	+	AG	A	A	A	A	+	+	+	-
<i>Proteus. species</i>	A/A with H <sub>2</sub> S	v	V	-	+	AG	-	V	v	+			+	+
<i>Pseudomonas .aeruginosa</i>	K/No change	V	-	+	+	-	-	-	-	-			-	+

Note: A/A = Acid slant / Acid butt,      + = Positive,   - = Negative

A=Acid production,

AG=Acid and gas production

# **ZONE SIZE INTERPRETATIVE CHART ACCORDING TO CLSI**

## **GUIDELINES-Kirby-Bauer Chart**

Sl. No.	Drug	Disk Content mcg	Resistant mm or less	Intermediate mm	Sensitive mm or more
For GNB 1	Ampicillin	10	13 mm	14-16 mm	17 mm
2	Co-trimoxazole	1.25/3.75	10	11-15	16
5	Ciprofloxacin	5	15	16-20	21
6	Gentamycin	10	12	13-14	15
7	Cefotaxime	30	14	15-22	23
8	Tetracycline	30	11	12-14	15
9	Chloramphenicol	30	12	13-17	18
11	Amoxycillin – Clavulanic acid	20/10	13	14-17	18



### **APPENDIX III:**

#### **Reagents required for ELISA :**

- Microwell plate, coated with monoclonal antibodies (mouse) against rotaviruses
- Sample-dilution buffer,
- Wash buffer, phosphate-buffered NaCl solution (10-fold concentrate);
- Positive control Inactivated monkey rotavirus (SA-11);
- Conjugate : Peroxidase-conjugated monoclonal antibody (mouse) against rotaviruses in stabilised protein solution;
- Substrate :Urea peroxide/TMB;
- Stop reagent, 1 N sulphuric acid
- Distilled or deionised water
- Test tubes
- Disposable pipettes
- Vortex mixer
- Micropipette for 50 -100  $\mu$ l and 1 ml volume
- Measuring cylinder (1000 ml)
- Stop clock, Washing unit for microtitration pipettes or multichannel pipettes (300  $\mu$ l)
- Photometer for microwell plates (450 nm and reference filter  $\geq$  600 nm where necessary)
- Filter paper (laboratory towels)
- Waste container containing 0.5 % hypochlorite solution

## *Bibliography*

## **BIBLIOGRAPHY**

1. A.K. Siddique et al ; Epidemiology of Rotavirus and Cholera in Children Aged Less Than Five Years in Rural Bangladesh; j health popul nutr 2011 Feb;29(1):1-8
2. Adissa Tran et al ; Prevalence of Rotavirus, Adenovirus, Norovirus, and Astrovirus Infections and Coinfections among Hospitalized Children in Northern France; journal of clinical microbiology, may 2010, p. 1943–1946 vol. 48, no. 5]
3. Ahmed HM et al. Molecular characterization of rotavirus gastroenteritis strains, Iraqi Kurdistan. Emerging Infectious Diseases, 2006, 12(5):1420–1422.
4. Ali M.Kheyami et al ; Rota virus infection in Saudi Arabia;Ann Saudi Med 26(3);May-June 2006.
5. Alicia Sa´nchez-Fauquier et al ; Diversity of Group A Human Rotavirus Types Circulating over a 4-Year Period in Madrid, Spain; journal of clinical microbiology, Apr. 2004, p. 1609–1613 Vol. 42, No. 4
6. AshkenaziS Shigellainfectionsin new sights. Semin Pediatr Infect Dis 2004 Oct; 15(4):246-52.
7. Bahrdwaj A et al. Does rota virus infection cause persistent diarrhoea in childhood? Tropical Gastroenterology, 1996, 17(1):18–21.
8. Bente Olesen et al ;Etiology of Diarrhea in Young Children in Denmark: a Case-Control Study; journal of clinical microbiology, aug. 2005, p. 3636–3641 Vol. 43, No. 8
9. Bern et al;The magnitude of the global problem of diarrhoeal disease: a ten year update;1992;Bull WHO,70,705-714.
10. Blacklow and Greenberg;1991;Viral gastroenteritis;N Engl J Med,325,252-264.
11. Bon et al; 1999;Prevalence of group A rotavirus, human calcivirus,astrovirus and adenovirus type 40 and 41 infections among children with acute gastroenteritis in Dijon,France;j Clin Microbiol;37,3055-3058
12. Bresee J, Glass RI, Ivanoff B, Gentsch JR (1999): Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries. Vaccine 17:2207–2222.

13. Bryce J et al ;WHO estimates of the causes of death in children,Lancet 2005;365:1147-1152.
14. Buesa J et al ; VP7 and VP4 genotypes among rotavirus strains recovered from children with gastroenteritis over a 3-year period in Valencia, Spain; eur j epidemiol. 2000 Jun;16(6):501-6.
15. Bui Thi Thu Hien et al;Diarrhoeagenic Escherichia coli and other causes of childhood diarrhea: a case control study in children living in a waste water use area in Hanoi,Vietnam;Journal of Medical Microbiology(2007);56;1086-1096.
16. Bushen OY,Cryptosporidiosis.In; Guerrant RL,editor Tropical infectious Diseases.principle,pathogens and practice.2<sup>nd</sup> edition;Elsevier;2006.p.1003-41.
- 16a. Centre for disease control.International Notes Outbreak of Hemorrhagic Colitis -- Ottawa, Canada .MMWR Morb Mortal wkly Rep 1983;32;133-4
17. Chrystie, I. L., B. M. Totterdell, and J. E. Banatvala. 1978. Asymptomatic endemic rotavirus infections in the newborn. Lancet i:1176–1178.
18. Communicable diseases: infections through the gastro-intestinal tract. Chapter 4. In: Gilles H, Lucas A, eds. Short textbook of public health medicine for the tropics, 4th ed. London, odder,2003.
19. David K.Turgeon. 2001. Laboratory approaches to infectious diarrhea. Gastro enterol Clin of North Am vol 30 no.3.sep 2001 ,693-707
20. Davidson et al structural and functional abnormalities of the small intestine in infants and young children with rota virus gastro enteritis,Acta Pediatr Scand 68:181-186,1979,1999
21. Desselberger et al,Topley and Wilsons virology , 10 th edn,Rota viruses,946-958
22. Du Pont HL: Guidelines on acute infectious disease in adults Am J Gastroenterology 92: 1962, 1997.
23. Dunn S J et al ;serotype and genotypic characterization of human serotype 10 rotavirus from asymptomatic neonates;J clin Microbiol 1993;31:165-9
24. DuPont H et al:Practice committee of the American College of Gastro enterology :Guidelines on acute infectious diarrhoea in adults.Am J Gastroenterol 92:1962-1975,1997
- 24a. Ebina et al;Prevention of rota virus infection by cow colostrums antibody against human rota viruses;Lancet 1983;322(8357):1029-1030.

25. Elizabeth Jane , acute gastroenteritis in children,BMJ,2007,334,35-40
26. Estimated rotavirus deaths for children under 5 years of age: 2004, 527 000. WorldHealthOrganization.
27. Fields virology vol 2, 5<sup>th</sup> edn,Estes et al ,Rota viruses,1917-1974
28. Forfur and Arneil's Textbook of pediatrics. Ed Neil McIntosh, Peter Holms and Rosalind Smyth. 6th edn. Rp 2004. p 679- 681.
29. Foster et al ; Hospital based surveillance to estimate the burden of rptavirus gastroenteritis among European children younger than 5 years of age;Pediatrics 2009;123:e393-e400.
30. Gagandeep Kang et al;Quantitation of Group A Rotavirus by Real Time Reverse Trancription Polymerase Chain Reaction; J Med Virol.2004;73(1):118-122]
31. Gentsch et al ; Review of G and P Typing Results from a Global Collection of Rotavirus Strains: Implications for Vaccine Development; The Journal of Infectious Diseases 1996; 174(suppl 1):830-6
32. Gopinath Balakrish Nair et al;Emerging trends in the etiology of enteric pathogens as evidenced from an active surveillance of hospitalized diarrhoeal patients in Kolkata,India; Gut Pathogens 2010, 2:4.
33. Greenough WB:Vibrio cholera and cholera. In Mandell GL Principles and practice of Infectious Diseases,ed4.New York, 1995,pp1934-1945.
34. Guerrant RL et al ,How intestinal bacteria cause disease.J Infec Dis 79:s331-337
35. Harrison's Principles of Internal Medicine. Kaspe, Braudwald, Fauci, Hauser longo Jamson.16th edn. (1) 2005. 754-759, 878-885,902-906 225
36. Iruka N Okeke, Adebayo Lamikandra et al., Characterization of E.coli strains from cases of childhood diarrhea in provincial southwestern Nigeria. J of Clin Microbiol, Jan 2000, p. 7-12.
37. J.J Kingston et al; Antimicrobial susceptibility and molecular characterization of Vibrio cholera from cholera outbreaks in Chennai;Indian J Microbiol (March 2009)49:84-88
38. James P. Nataro diarrheagenic escherichia coli clinical microbiology reviews, jan. 1998, p. 142–201 vol. 11, no. 1

39. John Albert, A.S.G Faruque, S.M. Faruque et al., Case control study of Enteropathogens associated with childhood diarrhea in Dhaka, Bangladesh. *J of Clin Microbiol*, Nov. 1999, p. 3458-3464.
40. Jones, G., Schultink, W. & Babilie, M. (2006). Child survival in India. *Indian J Pediatr* 73, 479–487
41. K.D Chaterjee, *Parasitology*, 13<sup>th</sup> edition, p 260-261.
42. Kaili fanapplication of Rejection Criteria for Stool Cultures for Bacterial Enteric Pathogens, *journal of clinical microbiology*, Aug. 1993, p. 2233-2235 .
43. Kannan Ramaswamy et al, infectious diarrhoea in children, *Gastro enterology clinics of North America* , vol 30, number 3 ,sep 2001,611-624.
44. Kapikian AZ et al visualization by immune electron microscopy of a 27 nm particle associated with acute infectious non bacterial gastro enteritis, *J Virol* 1972;10:1075
45. Khira Sdiri-Loulizi et al; Acute Infantile Gastroenteritis Associated with Human Enteric Viruses in Tunisia; *journal of clinical microbiology*, Apr. 2008, p. 1349–1355 Vol. 46, No. 4]
46. Khitam Muhsen et al; Incidence, Characteristics, and Economic Burden of Rotavirus Gastroenteritis Associated with Hospitalization of Israeli Children under 5 Years of Age, 2007–2008; *JID* 2009;200 (Suppl 1)]
47. Khuri-Bulos N, Al Khatib M. Importance of rotavirus as a cause of gastroenteritis in Jordan: hospital based study. *Scandinavian Journal of Infectious Diseases*, 2006, 38(8):639–644.
48. Kirkwood et al: report of the Australian rotavirus surveillance program, 2001/2002, Australian rotavirus surveillance program annual report 2002.
49. Koneman; colour atlas and textbook of diagnostic microbiology; sixth edition .chapter 6.
50. Kosek et al. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000, *Bull WHO* 2003;197-204
51. Laney dW, Cohen MB: Approach to the pediatric patient with diarrhea. *Gastroenterol Clin North am* 22:499, 1993.
52. Linhares et al; Longitudinal study of rota viral infections among children from Belem, Brazil; *Epidemiol Infect* 1989, 102(1); 129-145]

53. Lisa Lee et al; Hyperendemic Shigellosis in the United States: A Review of Surveillance Data for 1967–1988. *J Infect Dis* 1991;164;894-900
54. Lynne Shore Garcia, Diagnostic medical parasitology, 5<sup>th</sup> edition, ASM publication
55. M.Aminu et al; Epidemiology of Rota virus and Astro virus infections in children in Northwestern Nigeria; *Annals of African medicine*; vol.7; No.4; 2008:168-174.
56. Malek MA et al; The epidemiology of rotavirus diarrhoea in countries in the Eastern Mediterranean region; *J infect dis.* 2010 sep 1; 202 suppl: S12-22
57. Mandell , principles and practice of infectious diseases, 5<sup>th</sup> edn, Richard et al , principles and syndromes of enteric infection, chap 81, 1076-1093
58. Manual of rotavirus detection and characterization methods WHO/IVB/08.17 October 2009
59. Manuel R. Amieva 2005 , Important bacterial gastrointestinal pathogens in children: a pathogenesis perspective , *pediatric clinics of North America* 52, 749-777.
60. Mohammad Youssef et al; Bacterial, viral and parasitic enteric pathogens associated with acute diarrhea in hospitalized children from northern Jordan; *FEMS Immunology and Medical Microbiology* 28 (2000) 257-263.
- 61a. Moyo et al. Identification of diarrhoeagenic *Escherichia coli* isolated from infants and children in Dar es Salaam, Tanzania. *BMC Infectious diseases* 2007, 7:92 1186/1471-2334-7-92.
- 61b. Moyo et al; Prevalence of enteropathogenic viruses and molecular characterization of group A rota virus among children with diarrhea in Dar es Salaam Tanzania; *BMC public health* 2007; 7:359.
62. Moyo et al , Age specific aetiological agents of diarrhoea in hospitalized children aged less than five years in Dar es Salaam, Tanzania *BMC Pediatrics* 2011, 11:19
63. N.A. Cunliffe et al ; Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization; *Bulletin of the World Health Organization*, 1998, 76 (5): 525-537
64. Nakawesi et al ; Prevalence and factors associated with rotavirus infection among children admitted with acute diarrhea in Uganda; *BMC Pediatrics* 2010, 10:69

65. Nataro\* James P, and james b. kaper. Diarrhoeagenic Escherichia coli. Clinical microbiology reviews, Jan. 1998, p. 142–201 vol. 11, no. 1998,
66. Nelson Textbook of Paediatrics. Robert M. Kliegman, Hal B. Jensen, Richard E. Behrman Bonita F. Stanton (ed) 18th edn.2008. Vol I Ch196 & 197. P 1191-1196
67. Newly discovered rotavirus serotypes in 4 years of collecting samples from children with diarrheal syndromes . Medicinski Arhiv, 1992, 46(1,2):15–18.
68. Nishio O. et al; Rota virus infection among infants with diarrhoea in Vietnam;Pediatr Int.2000 Aug;42(4):422-4
69. O. Nafi et al ;Rotavirus gastroenteritis among children aged under 5 years in Al Karak, Jordan; Eastern Mediterranean Health Journal; Vol. 16 No.10 • 2010]
70. Pierre Van Damme et al ; Multicenter Prospective Study of the Burden of Rotavirus Acute Gastroenteritis in Europe, 2004–2005: The REVEAL Study; The Journal of Infectious Diseases 2007; 195:S4–16
71. P.K. Lorgelly ;Infantile gastroenteritis in the community: a cost-of-illness study; Epidemiol. Infect. (2008), 136, 34–43.]
72. P.saravanan et al; Rota virus infection among infants nd young children in chennai,south India;Indian journal of Medical Microbiology,2004;22(4):212-221
73. Pang et al;2000;Human calciviruses in acute gastroenteritis of young children in the community;J Infec Dis,181(suppl2);s288-s294.
74. Parashar UD et al ;Rotavirus and severe childhood diarrhoea;Emerg infect dis 2006;12:304-306
75. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565–72
76. Park K.Acute Diarrhea Diseases, in:Park K,editor.Parks textbook of preventive and social medicine,18<sup>th</sup> ed.Jabalpur:Banarasidas Bhanot;2005:171-174
77. Paton et al;pathogenesis and diagnosis of shiga toxin producing E,coli infections;Clin Microbio Rev 11;450;1998
- 77a. Patrick et al ;Evaluation of performance and potential clinical impact of prospect Shiga Toxin Escherichia coli Microplate Assay for Detection of shiga toxin producing E.coli in stool samples;Journal of Clinical Microbiology; Apr 2004,p.1652-1656.



78. PenelopeH.2005.acute diarrheal disease in children:epidemiology,prevention and treatment. *Infec Dis Clin N Am* 585-602.
79. Perez-Schael, I., G. Daoud, L. White, G. Urbina, N. Daoud, M. Perez, and J. Flores. 1984. Rotavirus shedding by newborn children. *J. Med. Virol.* 14: 127–136.
80. R.N kalaf and K.S Ghenghesh; Rota virus in children with diarrhoea in Tripoli,Libya; *Libyan J Med* 2011,6:6041
81. Ramachandran et al ;1996;unusual diversity of human G and P genotypes in India;*J Clin Microbiol*,34,436-9
82. Ramachandran et al ;1998 ; detection and characterization of novel rotavirus strains in the united states; *J Clin Microbiol*,36,3223-9.
83. Richard et al ,principles and syndromes of enteric infection,chap 81,1076-1093
84. Riyaz ,textbook of Paediatric gastroenterology,edition ,p 48-87.
85. Roger L.Shapiro et al;Antimicrobial resistant bacterial diarrhoea in rural western Kenya; *The journal of Infectious diseases* 2001;183;1701-4
86. Rohner P. et al., Etiological agents of infectious diarrhoea: Implications for requests for microbiol culture. *J Clin Microbiol* 35: 1427, 1997
87. Roshani Maharajan,Binod Lekhak,2007.detection of enteric bacterial pathogens in childhood diarrhoeal cases.*Scientific world*,vol.5;23-26
88. Ryuichi Uchida et al ; Molecular Epidemiology of Rotavirus Diarrhea among Children and Adults in Nepal: Detection of G12 Strains with P[6] or P[8] and a G11P[25] Strain; *journal of clinical microbiology*, oct. 2006, p. 3499–3505 vol. 44, no. 10]
89. Sambrook and russel, molecularcloning, A Laboratory Manual, Third Edition, Volume 2; Pages 8.20 – 8.22
90. S. Das et al Enteric pathogens in North Indian patients with diarrhoea;*Indian Journal of community medicine* vol.1;No.1;jan 2007.
91. S. S. R. Ajjampur et al; Closing the diarrhoea diagnostic gap in Indian children by the application of molecular techniques; *Journal of Medical Microbiology* (2008), 57, 1364–1368
92. Sethi SK et al Acute diarrhoea and rotavirus infections in young children in Kuwait. *Annals of Tropical Paediatrics*, 1984, 4:117–121.

93. Shukry S et al. Detection of enteropathogens in fatal and potentially fatal diarrhea in Cairo, Egypt. *Journal of Clinical Microbiology*, 1986, 24:959–962.
94. Sukumaran M et al ;Exclusive asymptomatic neonatal infections by human rota virus strains having subgroup I specificity and long RNA electropherotype;*Arch virol* 1992;126:239-51
95. T.I.Ogunsanya et al.;A study of the aetiological agents of childhood diarrhoea in Lagos, Nigeria; *J. Med. Microbiol.* - Vol. 40 (1994), 1&14
96. Teleb N. Update—EMRO surveillance network. *Rotavirus Surveillance News*, 2006, 1(3).
97. Topley and Wilson *Microbiology and Microbial infections*, 10th edition, M Altioegg and J Bockemuhl: *Escherichia Coli and Shigella* Chapter 40. 936-965.
98. Umesh D. Parashar Hospitalizations Associated with Rotavirus Diarrhea in the United States, 1993 through 1995: Surveillance Based on the New ICD-9-CM Rotavirus-Specific Diagnostic Code. *J Infec Disease* 1997;177:13-17
99. UNICEF/WHO, *Diarrhoea: Why children are still dying and what can be done*, 2009
100. Varshney et al ;Prevalence of and antigenic variation in serotype G10 rotaviruses and detection of serotype G3 strains in diarrheic calves:implications for the origin of G10P11 or P11 type reassortant asymptomatic strains in newborn children in India.*Arch virol* 2002;147:143-165.]
101. Velazquez FR, Matson DO, Calva JJ, Guerrero ML, Morrow AL, Carter-Campbell S, Glass RI, Estes MK, Pickering LK, Ruiz-Palacios GM (1996): Rotavirus infection in infants as protection against subsequent infections. *New England Journal of Medicine* 335:1022–1028.
102. Villa S, Guiscafne H, Martinez H, Munoz O, Gutierrez G. Seasonal diarrhoeal mortality among Mexican children. *Bull World Health Organ* 1999; 77:375–80
103. Vivek jain et al; Great Diversity of Group A Rotavirus Strains and High Prevalence of Mixed Rotavirus Infections in India; *journal of clinical microbiology*, Oct. 2001, p. 3524–3529 Vol. 39, No. 10
104. WHO Rota virus vaccines 2009
105. WHO, *The global burden of diseases:2004 update* 2008
106. WHO:Global networks for surveillance of rota virus gastroenteritis,2001-2008. *Weekly epidemiological report* 2008,83(47):421-425.

107. World Health Organization. Rotavirus vaccines. Weekly Epidemiological record 2007; 32:285-296
108. Wobudeya et al ;Breast feeding and the risk of rotavirus diarrhoea in hospitalized infants in Uganda: a matched case control study;BMC paediatrics 2011,11:17.]
109. Zuccotti et al ; Epidemiological and clinical features of rotavirus among children younger than 5 years of age hospitalized with acute gastroenteritis in Northern Italy; BMC Infectious diseases 2010,10:218
110. Zuckerman ;principles and practice of clinical virology;5<sup>th</sup> edn;Desselberger and Gray;viruses associated with acute diarrhoeal disease,249-256.

*Master chart*

STUDY GROUP																		
Sl. No.	Name	age	se x	stoo ls durn	fr eq	vomit ing	frequen cy	ab d pai n	fev er	bre ast feed	deh yd	cons is	bloo dy	parasite	isolate/s	antimicrobial sensitivity	rota ELI SA	GENOTYP E
1	prathipal	7 mths	m c	72H rs st	7 to 10	>72hr s vom	4-6 epi	ab d pai n-	fev -	bf+	sev ere	wat ery	b-		V.cholerae	sen to tet,ampi, chlor res to cot	rotn eg	
2	muralidhar an	9mth s	m c	>72 hrs st	7 to 10	no vom		ab d pai n-	fev +	bf-	no	wat ery	b-	EH cyst	E.coli		rotn eg	
3	boominath an	10 mths	m c	48 hrs st	4 to 6	48hrs vom	1-3 epi	ab d pai n-	fev -	bf+	som e	sem i	b-		E.coli,Enter ococci		rotn eg	
4	kaaviya	10mt hs	fc	72hr s st	>1 0	no vom		ab d pai n-	fev -	bf+	no	wat ery	b-		E.coli		rotn eg	
5	sanjay	8mth s	m c	>72 hrs st	>1 0	48hrs vom	4-6 epi	ab dp ne g	fev +	bf+	sev ere	wat ery	b-		E.coli		rot pos	G1P[8]
6	mukesh	27mt hs	fc	>72 hrs st	7 to 10	no vom		ab d pai n-	fev -	bf+	no	sem i	b-		S.aureus,ent ero		rotn eg	
7	elakiya	12mt hs	fc	48hr s st	>1 0	no vom		ab d pai n-	fev +	bf+	som e	wat ery	b+		Ent.h'gic E.coli		rotn eg	
8	hariprakas h	11mt hs	m c	72hr s st	>1 0	no vom		ab d pai n-	fev -	bf+	no	wat ery	b-		E.coli		rotn eg	

9	prabhu	15mths	mc	72hrs st	4 to 6	72hrs vom	1-3 epi	abdp neg	fev +	bf-	severe	watery	b-		E.coli		rot pos	G1P[8]
10	mercy	6mths	fc	48hrs st	7 to 10	48hrs vom	4-6 epi	abdp neg	fev +	bf-	som e	watery	b-		enterococci		rot pos	G2P[4]
11	tamil	5mths	mc	>72 hrs st	4 to 6	no vom		abd pain-	fev -	bf+	no	watery	b-		S.aureus		rotn eg	
12	Shalini	6mths	fc	48hrs st	7 to 10	24hrs vom	1-3 epi	abd pain-	fev +	bf+	som e	watery	b-		E.coli		rotn eg	
13	arshini	4.5 mths	fc	24hrs st	4 to 6	no vom		abd pain-	fev -	bf+	no	watery	b-		E.coli		rotn eg	
14	kumaera	12mths	fc	24hrs st	>10	24hrs vom	4-6 epi	abd pain-	fev -	bf+	severe	semi	b+		E.coli		rotn eg	
15	mukilan	8mths	mc	72hrs st	4 to 6	no vom		abdp neg	fev -	bf+	som e	watery	b-		E.coli		rot pos	not typed
16	vinodhini	9mths	fc	48hrs st	4 to 6	24 hrs vom	1-3 epi	abd pain-	fev +	bf+	no	semi	b-		E.coli,K.ox y		rotn eg	
17	deepika	9mths	fc	72hrs st	7 to 10	72hrs vom	1-3 epi	abdp neg	fev -	bf+	som e	watery	b-		E.coli		rot pos	untypeable
18	jeyasri	8mths	fc	72hrs st	7 to	72hrs vom	1-3 epi	abd	fev +	bf+	som e	semi	b-		k.oxy,E.coli		rotn eg	

					10			pai n-										
19	abdul aakif	12mt hs	fc	48hr s st	4 to 6	no vom		ab d pai n-	fev -	bf+	no	wat ery	b-		E.coli,Enter o		rotn eg	
20	kaavya	18mt hs	fc	72hr s st	4 to 6	72hrs vom	1-3 epi	ab d pai n-	fev -	bf-	som e	wat ery	b-		E.coli		rotn eg	
21	Faariya	18mt hs	fc	48 hrs st	7 to 10	48hrs vom	4-6 epi	ab dp ne g	fev +	bf-	sev ere	wat ery	b-		E.coli		rot pos	G1P[8]
22	monish	8mth s	m c	48 hrs st	7 to 10	48hrs vom	1-3 epi	ab d pai n-	fev +	bf+	som e	wat ery	b-		E.coli		rotn eg	
23	rithik	15mt hs	m c	48 hrs st	>1 0	no vom		ab d pai n-	fev +	bf+	sev ere	wat ery	b-		E.coli		rotn eg	
24	sahin banu	6mth s	fc	48 hrs st	7 to 10	no vom		ab d pai n-	fev +	bf+	sev ere	wat ery	b-		E.coli		rotn eg	
25	dharani	15mt hs	m c	48hr s st	4 to 6	48hrs vom	1-3 epi	ab d pai n-	fev +	bf+	no	wat ery	b+		E.coli,pseud o		rotn eg	
26	ilakiyan	54mt hs	m c	24hr s st	4 to 6	no vom		ab d pa +	fev +	bf+	no	wat ery	b+		E.coli,S.flex neri	sens to cip,gen,cefo,am clav,res to amp,cot	rotn eg	
27	shunmuga priya	15mt hs	fc	24hr s st	>1 0	24hrs vom	1-3 epi	ab d pai n-	fev -	bf+	som e	wat ery	b-		K.pneum,E. coli		rotn eg	

28	vinthya	9mths	fc	48hrs st	4 to 6	48hrs vom	1-3 epi	ab dp ne g	fev +	bf+	no	wat ery	b-		E.coli		rot pos	not typed
29	tamilarasi	54mths	fc	48 hrs st	4 to 6	no vom		ab d pai n-	fev -	bf+	no	wat ery	b-	EH cyst	E.coli		rotn eg	
30	jeganathan	10mths	mc	24hrs st	7 to 10	24hrs vom	4-6 epi	ab d pai n-	fev +	bf+	som e	wat ery	b-		E.coli		rotn eg	
31	prithika	5mths	fc	>72 hrss t	7 to 10	no vom		ab d pai n-	fev -	bf+	no	wat ery	b-		E.coli		rotn eg	
32	valarnila	12mths	fc	24hrs st	>10	24hrs vom	4-6 epi	ab dp ne g	fev +	bf-	som e	wat ery	b-		E.coli		rot pos	not typed
33	Aashika	17mths	fc	72hrs st	4 to 6	48hrs vom	1-3 epi	ab d pai n-	fev +	bf-	no	wat ery	b+		E.coli		rotn eg	
34	Rohit	11mths	mc	48 hrs st	>10	48hrs vom	1-3 epi	ab d pai n-	fev +	bf-	som e	wat ery	b+		Enth'gic.col i		rotn eg	
35	mukesh	5mths	mc	24hrs st	4 to 6	24hrs vom	1-3 epi	ab d pai n-	fev -	bf+	no	sem i	b-		E.coli,Pseu do		rotn eg	
36	shyamala	7mths	fc	48 hrs st	4 to 6	no vom		ab d pai n-	fev -	bf+	no	sem i	b-		K.pneum,E. coli		rotn eg	
37	sumaiya	9mths	fc	48 hrs	7 to	48hrs vom	4-6 epi	ab dp	fev	bf+	severe	wat ery	b-		E.coli		rot pos	not typed



				st	10			ne g	+									
38	nithin	11mt hs	m c	72hr s st	>1 0	24hrs vom	4-6 epi	ab d pai n-	fev +	bf+	som e	wat ery	b-		pseudo,E.co li		rotn eg	
39	padmanab an	15mt hs	m c	>72 hrss t	7 to 10	>72hr s vom	4-6 epi	ab d pai n-	fev +	bf+	sev ere	wat ery	b-		E.coli		rotn eg	
40	raksana	7mth s	fc	48 hrs st	>1 0	no vom		ab d pai n-	fev -	bf -	no	sem i	b-		E.coli,S.flex neri	sens to cip,gen,res to cefo,amclav, amp,cot	rotn eg	
41	jayalaksh mi	8mth s	fc	>72 hrss t	4 to 6	24hrs vom	1-3 epi	ab d pai n-	fev +	bf+	no	wat ery	b-		E.coli		rotn eg	
42	krishna	36mt hs	m c	>72 hrss t	7 to 10	72hrs vom	1-3 epi	ab dp ne g	fev -	bf+	som e	wat ery	b-		E.coli		rot pos	not typed
43	swathy	12mt hs	fc	24hr s st	>1 0	48hrs vom	1-3 epi	ab d pai n-	fev +	bf+	sev ere	wat ery	b-		E.coli		rotn eg	
44	lathifa begum	8mth s	fc	48 hrs st	4 to 6	no vom		ab d pai n-	fev +	bf-	no	wat ery	b-		E.coli,S.flex neri	sens to cip,gen,cefo,am clav,res to amp,cot	rotn eg	
45	thangaman i	15mt hs	m c	24hr s st	4 to 6	24hrs vom	1-3 epi	ab d pai n-	fev +	bf-	no	wat ery	b-		E.coli		rotn eg	
46	tamilselva n	12mt hs	m c	24hr s st	7 to 10	24hrs vom	4-6 epi	ab d pai n-	fev +	bf+	som e	wat ery	b+		E.coli,S.flex neri	sens to cip,gen,res to cefo,amclav, amp,cot	rotn eg	

47	yazhini	24mt hs	fc	24hr s st	4 to 6	24hrs vom	4-6 epi	ab d pai n-	fev +	bf-	no	wat ery	b-	EH cyst	E.coli		rotn eg	
48	shek rehman	10mt hs	m c	72hr s st	4 to 6	>72hr s vom	1-3 epi	ab dp ne g	fev +	bf-	som e	wat ery	b-		E.coli		rot pos	not typed
49	srisanjev	8mth s	m c	>72 hrss t	7 to 10	>72hr s vom	1-3 epi	ab d pai n-	fev -	bf+	sev ere	wat ery	b-		E.coli		rotn eg	
50	nivedha	24mt hs	fc	>72 hrss t	7 to 10	no vom		ab d pai n-	fev +	bf-	som e	wat ery	b-		E.coli,K.ox y		rotn eg	
51	sabarish	12mt hs	m c	24hr s st	7 to 10	no vom		ab d pa +	fev -	bf-	som e	wat ery	b-	Giardia	E.coli		rotn eg	
52	saravanan	36mt hs	m c	24hr s st	4 to 6	24hrs vom	1-3 epi	ab d pa +	fev +	bf-	no	wat ery	b+		E.coli,S.flex neri	sens to cip,gen,cefo,am clav,res to amp,cot	rotn eg	
53	tejes	8mth s	fc	48 hrs st	7 to 10	48hrs vom	1-3 epi	ab dp ne g	fev +	bf-	sev ere	wat ery	b-		E.coli		rot pos	untypeable
54	rakesh	8mth s	m c	24hr s st	7 to 10	24hrs vom	1-3 epi	ab d pai n-	fev -	bf+	som e	wat ery	b-		E.coli		rotn eg	
55	tamilarasa n	30mt hs	m c	72hr s st	>1 0	no vom		ab d pai n-	fev +	bf-	som e	wat ery	b+		E.coli		rotn eg	
56	dharshini	54mt hs	fc	24hr s st	>1 0	no vom		ab d	fev +	bf-	no	wat ery	b+		E.coli,S.dys	sens to cip,gen,cefo,am	rotn eg	

							pa +								clav,res to amp,cot		
57	divyadarsh ini	24mt hs	fc	72hr s st	4 to 6	no vom	ab d pa +	fev -	bf-	som e	sem i	b-		E.coli,S.flex neri	sens to cip,gen,res to cefo,amclav, amp,cot	rotn eg	
58	monisha	12mt hs	fc	>72 hrss t	4 to 6	72hrs vom	ab d pai n-	fev +	bf+	no	wat ery	b-		E.coli		rotn eg	
59	Ezhilarasa n	8mth s	m c	72hr s st	4 to 6	72hrs vom	ab d pai n-	fev +	bf-	som e	wat ery	b-		E.coli		rotn eg	
60	prithiv	16mt hs	m c	72hr s st	4 to 6	72hrs vom	ab dp ne g	fev -	bf-	no	wat ery	b-		E.coli		rot pos	not typed
61	jithesh	12mt hs	m c	>72 hrss t	4 to 6	>72hr s vom	ab d pai n-	fev -	bf+	no	sem i	b-		E.coli		rotn eg	
62	sreeharini	7mth s	fc	>72 hrss t	4 to 6	no vom	ab d pai n-	fev +	bf+	no	wat ery	b-		E.coli,pseud o		rotn eg	
63	vishali	8mth s	fc	48 hrs st	4 to 6	48hrs vom	ab d pai n-	fev +	bf+	no	wat ery	b-		E.coli,S.flex neri	sens to cip,gen,cefo,am clav,res to amp,cot	rotn eg	
64	sanjay	36mt hs	m c	24hr s st	>1 0	24hrs vom	ab d pai n-	fev +	bf-	sev ere	wat ery	b-		E.coli		rotn eg	
65	dharani	7mth s	fc	24hr s st	4 to 6	no vom	ab d pai n-	fev -	bf+	no	wat ery	b-		proteus,s.au reus		rotn eg	

66	afra fathima	12mths	fc	>72 hrss t	7 to 10	no vom		ab dp ne g	fev -	bf+	som e	wat ery	b-		E.coli		rot pos	G2P[4]
67	rajesh	8mths	mc	24hrs st	4 to 6	>72hrs vom	4-6 epi	ab d pai n-	fev +	bf-	no	wat ery	b-		E.coli		rotn eg	
68	rahul	27mths	mc	72hrs st	>10	72hrs vom	1-3 epi	ab d pai n-	fev +	bf+	severe	wat ery	b-		E.coli		rotn eg	
69	yamini	22mths	fc	72hrs st	7 to 10	72hrs vom	4-6 epi	ab d pai n-	fev -	bf-	no	semi	b-		E.coli		rotn eg	
70	monisha	8mths	fc	24hrs st	7 to 10	no vom		ab d pa +	fev -	bf-	no	wat ery	b-	cryptosporidium	E.coli		rotn eg	
71	thannarasu	15mths	mc	24hrs st	7 to 10	24hrs vom	1-3 epi	ab d pa +	fev +	bf-	no	wat ery	b-		S.flexneri	sens to cip,gen,cefo,am clav,res to amp,cot	rotn eg	
72	suriya	12mths	mc	24hrs st	>10	24hrs vom	4-6 epi	ab dp ne g	fev +	bf-	som e	wat ery	b-		K.oxy,		rot pos	not typed
73	aayisha siddika	42m	fc	>72 hrss t	7 to 10	no vom		ab d pa +	fev +	bf+	som e	semi	b+		E.coli,S.flexneri	sens to cip,gen,cefo,am clav,res to amp,cot	rotn eg	
74	yuvaraj	21mths	mc	24hrs st	4 to 6	24hrs vom	1-3 epi	ab d pai n-	fev +	bf-	no	wat ery	b-		E.coli		rotn eg	
75	gunal	10mths	mc	24hrs st	4 to	24hrs vom	4-6 epi	ab d	fev -	bf+	no	wat ery	b-		k.oxy,E.coli		rotn eg	

					6			pai n-										
76	lathika	8mth s	fc	72hr s st	4 to 6	24hrs vom	4-6 epi	ab d pai n-	fev -	bf+	sev ere	sem i	b +		EH E.coli		rotn eg	
77	Dhanalaks hmi	36mt hs	fc	>72 hrss t	4 to 6	48hrs vom	4-6 epi	ab d pai n-	fev +	bf-	no	wat ery	b-		E.coli		rotn eg	
78	jothi	36mt hs	fc	48 hrs st	4 to 6	no vom	4-6 epi	ab d pa +	fev +	bf-	no	wat ery	b +	EH cyst	S.paratyphi A	sen to cip,cefo,amclav ,gen, cot,ampi	rotn eg	
79	Monish babu	36mt hs	m c	72hr s st	>1 0	48hrs vom	4-6 epi	ab d pa +	fev +	bf-	som e	wat ery	b-		k.oxy,E.coli		rotn eg	
80	Srikrishna n	9mth s	m c	72hr s st	4 to 6	72hrs vom	7-10 epi	ab d pai n-	fev +	bf+	no	wat ery	b-		K.oxy		rotn eg	
81	Ashika	10mt hs	fc	24hr s st	4 to 6	no vom		ab dp ne g	fev -	bf-	som e	wat ery	b-		E.coli		rot pos	not typed
82	Tamilarasu	11mt hs	m c	24hr s st	4 to 6	24hrs vom	1-3 epi	ab d pai n-	fev +	bf+	no	wat ery	b-		E.coli,k.oxy		rotn eg	
83	Maheswar an	12mt hs	m c	>72 hrs st	4 to 6	no vom		ab d pai n-	fev +	bf-	no	wat ery	b+		S.flexneri,E .coli	sens to cip,gen,cefo,am clav,res to amp,cot	rotn eg	
84	Iniya	15mt hs	fc	72hr s st	4 to 6	72hrs vom	1-3 epi	ab d pai n-	fev -	bf-	no	wat ery	b-		E.coli		rotn eg	

85	Akshara	15mths	fc	>72 hrs st	4 to 6	no vom		abd pa +	fev +	bf-	som e	wat ery	b+		E.coli		rotn eg	
86	Sanjana	7mths	fc	72hrs st	4 to 6	no vom		abd pain-	fev -	bf+	no	wat ery	b-		K.oxy		rotn eg	
87	Thiyagarajan	9mths	mc	>72 hrs st	4 to 6	24hrs vom	1-3 epi	abd pain-	fev +	bf+	som e	wat ery	b-		E.coli		rotn eg	
88	Joefelix	8mths	mc	24hrs st	7 to 10	24hrs vom	1-3 epi	abdp neg	fev +	bf-	no	wat ery	b-		E.coli		rot pos	untypeable
89	Gokulesh	36mths	mc	>72 hrs st	4 to 6	no vom		abd pa +	fev -	bf+	som e	wat ery	b-	Giardia	E.coli		rotn eg	
90	Shalini	6mths	fc	48hrs st	4 to 6	24hrs vom	1-3 epi	abd pain-	fev -	bf-	no	wat ery	b-		E.coli,K.oxy		rotn eg	
91	Kaavya	10mths	fc	>72 hrs st	7 to 10	no vom		abd pain-	fev +	bf-	no	wat ery	b-		pseudo,E.coli		rotn eg	
92	Mohanakrishnan	9mths	mc	72hrs st	7 to 10	48hrs vom	1-3 epi	abd pain-	fev +	bf-	som e	wat ery	b-		E.coli		rotn eg	
93	Dharshan	6mths	mc	72hrs st	4 to 6	>72hrs vom	1-3 epi	abdp neg	fev -	bf+	no	wat ery	b-		E.coli		rot pos	G10P[untypeable]
94	Divya	36mths	fc	>72 hrs	7 to	no vom		abd	fev -	bf-	no	wat ery	b-	cryptosporidium	K.oxy		rotn eg	

				st	10			pa +										
95	Nithilan	18mt hs	m c	>72 hrs st	>1 0	no vom		ab d pa +	fev +	bf-	som e	wat ery	b+		E.coli,S.flex neri	sens to cip,gen,cefo,am clav,res to amp,cot	rotn eg	
96	Mohan kumar	7.5m ths	m c	48hr s st	4 to 6	no vom		ab d pa +	fev +	bf+	sev ere	wat ery	b-		E.coli,K.ox y		rotn eg	
97	Mani	8mth s	m c	72hr s st	4 to 6	no vom		ab d pai n-	fev +	bf-	no	wat ery	b-		E.coli		rotn eg	
98	Agilesh	8mth s	m c	72hr s st	4 to 6	48hrs vom	1-3 epi	ab d pai n-	fev -	bf-	som e	wat ery	b-		Proteus		rotn eg	
99	Jeeva	36mt hs	m c	48hr s st	4 to 6	no vom		ab d pa +	fev +	bf+	no	wat ery	b-		entero,E.col i		rotn eg	
100	Sriram	18mt hs	m c	48hr s st	4 to 6	no vom		ab d pai n-	fev +	bf+	no	wat ery	b-		E.coli		rotn eg	
101	Tamil sekuvara	14mt hs	m c	48hr s st	4 to 6	no vom		ab d pai n-	fev -	bf+	no	wat ery	b-		E.coli		rotn eg	
102	Lokesh	18mt hs	m c	>72 hrs st	4 to 6	72hrs vom	1-3 epi	ab d pai n-	fev -	bf+	no	wat ery	b-		pseudo,E.co li		rotn eg	
103	Prabakaran	24mt hs	m c	48hr s st	7 to 10	48hrs vom	4-6 epi	ab dp ne g	fev +	bf-	som e	wat ery	b-		E.coli		rot pos	G1P[8]

104	Vignesh	18mt hs	m c	>72 hrs st	>1 0	>72hr s vom	4-6 epi	ab d pai n-	fev +	bf-	som e	wat ery	b-		E.coli		rotn eg	
105	Naren bose	18mt hs	m c	24hr s st	4 to 6	24hrs vom	1-3 epi	ab d pai n-	fev +	bf+	no	wat ery	b-		E.coli		rotn eg	
106	Kamalesh	11mt hs	m c	72hr s st	4 to 6	no vom		ab d pai n-	fev -	bf-	no	sem i	b+		S.flexneri,E .coli	sens to cip,gen,cefo,am clav,res to amp,cot	rotn eg	
107	Sanjay	36mt hs	m c	>72 hrs st	4 to 6	no vom		ab d pa +	fev +	bf-	no	wat ery	b-		E.coli,enter o		rotn eg	
108	afra fathima	12mt hs	fc	>72 hrs st	7 to 10	no vom		ab d pai n-	fev -	bf-	sev ere	wat ery	b-		E.coli		rotn eg	
109	yuvraj	21mt hs	m c	24hr s st	4 to 6	24hrs vom	1-3 epi	ab d pai n-	fev +	bf-	no	wat ery	b-		proteus		rotn eg	
110	gunal	10mt hs	m c	24hr s st	7 to 10	24hrs vom	4-6 epi	ab dp ne g	fev +	bf+	no	wat ery	b-		k.oxy		rot pos	not typed
111	rahul	12mt hs	m c	72hr s st	7 to 10	no vom		ab d pa +	fev +	bf-	sev ere	sem i	b+		S.flexneri,E .coli	sens to cip,gen,cefo,am clav,res to amp,cot	rotn eg	
112	Abudali	51mt hs	m c	24hr s st	7 to 10	24hrs vom	4-6 epi	ab d pai n-	fev +	bf+	som e	wat ery	b-	EH cyst	E.coli		rotn eg	
113	Katheeja suhaina	24mt hs	fc	48hr s st	4 to	no vom		ab d	fev +	bf-	no	wat ery	b-		E.coli		rotn eg	



					6			pai n-										
114	Dhanush	24mt hs	m c	48hr s st	4 to 6	no vom		ab d pai n-	fev +	bf-	no	wat ery	b-		E.coli		rotn eg	
115	Santhosh	18mt hs	m c	>72 hrs st	4 to 6	>72hr s vom	4-6 epi	ab d pai n-	fev +	bf+	som e	wat ery	b-		E.coli		rotn eg	
116	Bavani	24mt hs	fc	48hr s st	>1 0	24hrs vom	1-3 epi	ab d pai n-	fev +	bf-	no	wat ery	b-		k.oxy,E.coli		rotn eg	
117	Jaidev	9mth s	m c	24hr s st	4 to 6	no vom		ab d pai n-	fev +	bf+	no	wat ery	b-		E.coli		rotn eg	
118	Manoj	7mth s	m c	>72 hrs st	7 to 10	no vom		ab dp ne g	fev -	bf+	som e	wat ery	b-		E.coli		rot pos	not typed
119	Jayananthi ni	18mt hs	fc	72hr s st	7 to 10	72hrs vom	4-6 epi	ab d pai n-	fev +	bf-	no	wat ery	b-		E.coli		rotn eg	
120	Valanshika	12mt hs	fc	72hr s st	4 to 6	no vom		ab d pai n-	fev +	bf-	no	wat ery	b-		E.coli		rotn eg	
121	Balaji	18mt hs	m c	24hr s st	4 to 6	no vom		ab d pai n-	fev -	bf+	no	sem i	b-		E.coli		rotn eg	
122	Angel christina	12mt hs	fc	>72 hrs st	7 to 10	72hrs vom	4-6 epi	ab d pa +	fev +	bf-	no	wat ery	b+		S.typhimuri um	sen to cip,cefo,amclav ,gen, cot res to ampi	rotn eg	

123	Tarun	18mths	mc	72hrsst	>10	24hrsvom	4-6epi	abdpne g	fev+	bf+	severe	watery	b-		E.coli		rot pos	not typed
124	Mani	8mths	mc	72hrsst	4 to 6	24hrsvom	4-6epi	abd pain-	fev+	bf-	no	watery	b-		proteus,E.coli		rotn eg	
125	Jacob	7mths	mc	24hrsst	4 to 6	24hrsvom	4-6epi	abd pain-	fev-	bf+	no	watery	b-		E.coli		rotn eg	
126	Praveen kumar	18mths	mc	48hrsst	7 to 10	no vom		abd pain-	fev-	bf-	no	watery	b-		E.coli		rotn eg	
127	vijoovan	6mths	mc	>72hrsst	4 to 6	no vom		abd pain-	fev+	bf+	som e	semi	b-		k.oxy.E.coli		rotn eg	
128	Sasikumar	54mths	mc	72hrsst	4 to 6	24hrsvom	4-6epi	abd pain-	fev+	bf+	no	watery	b-	Ascaris egg	k.oxy		rotn eg	
129	Vishwa	18mths	mc	24hrsst	4 to 6	24hrsvom	4-6epi	abd pain-	fev-	bf+	severe	watery	b-		E.coli		rotn eg	
130	Srinivas	48mths	mc	24hrsst	4 to 6	no vom		abd pain-	fev-	bf-	som e	semi	b-		E.coli,proteus		rotn eg	
131	Akash	18mths	mc	24hrsst	4 to 6	24hrsvom	1-3epi	abd pain-	fev-	bf-	no	semi	b-		E.coli		rotn eg	
132	Ayyanaar	32mths	mc	24hrsst	4 to	no vom		abd	fev-	bf+	no	watery	b-		pseudo,E.coli		rotn eg	

					6			pai n-										
133	Mohammed Farook	11mths	mc	72hrs st	7 to 10	72hrs vom	4-6 epi	abdp ne g	fev +	bf+	severe	watery	b-		E.coli		rot pos	G1P[8]
134	Sri sanjeev	8mths	mc	>72hrs st	7 to 10	>72hrs vom	4-6 epi	abd pai n-	fev -	bf+	no	watery	b-		k.oxy,entero		rotn eg	
135	sree	15mths	mc	48hrs st	4 to 6	no vom		abd pa +	fev +	bf-	no	semi	b-		E.coli		rotn eg	
136	Shekrehman	10mths	mc	72hrs st	7 to 10	72hrs vom	1-3 epi	abd pai n-	fev -	bf+	severe	semi	b-		entero,E.coli		rotn eg	
137	Nivedha	24mths	fc	>72hrs st	7 to 10	no vom		abd pai n-	fev +	bf-	som e	watery	b-		E.coli		rotn eg	
138	Naresh kumar	21mths	mc	>72hrs st	4 to 6	72hrs vom	1-3 epi	abd pai n-	fev +	bf-	no	watery	b-		E.coli		rotn eg	
139	Rithika	18mths	fc	24hrs st	4 to 6	no vom		abd pai n-	fev +	bf+	no	watery	b-		k.oxy		rotn eg	
140	Sylvia	9mths	fc	48hrs st	4 to 6	48hrs vom	1-3 epi	abd pai n-	fev +	bf+	severe	watery	b-		EH E.coli		rotn eg	
141	Muvin kumar	7mths	mc	48hrs st	4 to 6	no vom		abd pai n-	fev -	bf+	no	watery	b-		E.coli		rotn eg	

142	Sahistha	10mt hs	fc	48hr s st	4 to 6	no vom		ab d pai n-	fev -	bf+	sev ere	wat ery	b-		S.aureus,E.c oli		rotn eg	
143	Vandhana	24mt hs	fc	24hr s st	4 to 6	24hrs vom	1-3 epi	ab d pa +	fev -	bf-	no	wat ery	b+		S.flexneri	sens to cip,gen,cefo,am clav,res to amp,cot	rotn eg	
144	Doyal	12mt hs	m c	24hr s st	7 to 10	24hrs vom	4-6 epi	ab dp ne g	fev +	bf-	no	wat ery	b-		E.coli		rot pos	G1P[8]
145	David jebaselvan	12mt hs	m c	48hr s st	4 to 6	48hrs vom	1-3 epi	ab d pai n-	fev +	bf+	no	sem i	b-		pseudo,E.co li		rotn eg	
146	Uday	9mth s	m c	72hr s st	4 to 6	no vom		ab d pai n-	fev -	bf+	sev ere	wat ery	b-		E.coli		rotn eg	
147	vijayakum ari	12mt hs	fc	24hr s st	4 to 6	no vom		ab d pa +	fev +	bf-	no	sem i	b-		k.oxy,E.coli		rotn eg	
148	pooja sree	18mt hs	fc	48hr s st	7 to 10	no vom		ab d pa +	fev +	bf+	no	wat ery	b-		E.coli		rotn eg	
149	swathi	9mth s	fc	>72 hrs st	4 to 6	>72hr s vom	1-3 epi	ab d pai n-	fev +	bf+	no	wat ery	b-		E.coli		rotn eg	
150	jothi	24mt hs	fc	48hr s st	4 to 6	48hrs vom	4-6 epi	ab d pai n-	fev +	bf+	no	wat ery	b-		E.coli		rotn eg	

CONTROLS						
SL. NO	AGE	SEX	BREAST FEED	BACTERIA	PARASITE	ROTA VIRUS
1	6mths	mc	bf+	E.coli		rot neg
2	12mths	mc	bf+	E.coli,k.oxy		rot neg
3	18mths	fc	bf+	E.coli		rot neg
4	15mths	fc	bf-	E.coli,pseudo		rot neg
5	30mths	mc	bf+	k.oxy	EH cyst	rot neg
6	7mths	mc	bf+	E.coli		rot neg
7	8mths	fc	bf+	E.coli,k.oxy		rot neg
8	36mths	fc	bf+	k.oxy		rot neg
9	18mths	fc	bf+	E.coli		rot neg
10	9mths	mc	bf+	E.coli		rot neg
11	6mths	fc	bf+	E.coli,k.oxy		rot neg
12	32mths	mc	bf+	k.oxy		rot neg
13	24mths	mc	bf+	E.coli		rot neg
14	12mths	fc	bf+	E.coli		rot neg
15	24mths	fc	bf+	pseudo		rot neg
16	50mths	mc	bf-	E.coli	EH cyst	rot neg
17	8mths	mc	bf+	E.coli		rot neg
18	21mths	mc	bf+	E.coli		rot neg
19	36mths	mc	bf-	k.oxy		rot neg
20	6mths	mc	bf+	E.coli		rot neg
21	12mths	mc	bf+	E.coli,entero		rot neg
22	30mths	mc	bf-	k.oxy		rot neg
23	24mths	fc	bf+	E.coli,k.oxy		rot neg
24	9mths	fc	bf+	E.coli		rot neg
25	36mths	fc	bf-	k.oxy		rot neg
26	12mths	mc	bf+	E.coli		rot neg
27	12mths	fc	bf+	E.coli,k.oxy		rot neg
28	40mths	mc	bf-	E.coli	EH cyst	rot neg
29	9mths	fc	bf+	E.coli		rot neg

30	18mths	mc	bf+	E.coli,proteus		rot neg
31	7mths	mc	bf+	E.coli		rot neg
32	7.5mths	fc	bf+	E.coli		rot neg
33	32mths	mc	bf+	pseudo		rot neg
34	24mths	mc	bf-	E.coli,k.oxy		rot neg
35	12mths	mc	bf+	E.coli		rot neg
36	9mths	fc	bf+	E.coli		rot neg
37	18mths	fc	bf-	S.aureus		rot neg
38	8mths	mc	bf+	E.coli		rot neg
39	24mths	mc	bf+	E.coli		rot neg
40	8.5mths	mc	bf+	E.coli		rot neg
41	42mths	fc	bf-	proteus		rot neg
42	12mths	fc	bf+	E.coli,k.oxy		rot neg
43	9mths	mc	bf+	E.coli		rot neg
44	8mths	fc	bf+	E.coli		rot neg
45	54mths	mc	bf-	entero	EH cyst	rot neg
46	32mths	fc	bf+	E.coli		rot neg
47	18mths	mc	bf+	E.coli		rot neg
48	12mths	fc	bf+	E.coli,k.oxy		rot neg
49	24mths	fc	bf+	E.coli		rot neg
50	9mths	mc	bf-	k.oxy		rot neg

*Key to Master chart*

### **Key to Master chart**

mc	-	male child
fc	-	female child
bf	-	breast feeding status
fev	-	fever
abd pain	-	abdominal pain
vom	-	vomiting
b	-	blood stained
E.coli	-	Escherichia coli
K.oxy	-	Klebsiella oxytoca
K.pneum	-	Klebsiella pneumoniae
Pseudo	-	Pseudomonas sp
Entero	-	Enterococci
S.aureus	-	Staphylococcus aureus
V.cholerae	-	Vibrio cholerae
EH cyst	-	Entamoeba histolytica
Giardia	-	Giardia lamblia
Cryptosporidium	-	Cryptosporidium parvum
Rot	-	Rota virus antigen
cip	-	ciprofloxacin
gen	-	gentamycin
cefo	-	cefotaxime
amclav	-	amoxy clavulanic acid
amp	-	ampicillin
cot	-	cotrimoxazole
tet	-	tetracycline
chlor	-	chloramphenicol
sen	-	sensitive,
res	-	resistant



*Proforma*

## **PROFORMA**

Name :  
Age :  
Sex : male/female  
Address :  
OP/IP No :  
Micro ID No :  
Complaints :  
Loose stools :  
Nature of stool : watery/bloody/mucus  
Frequency : 4-6/7-10/>10 episodes/day  
Duration : 24 hrs/48 hrs/72 hrs/>72 hrs  
Vomiting :  
Duration :  
Abdominal pain :  
Duration :  
Fever :  
Duration :  
Cough/running nose:  
Duration :  
Difficulty in feeding:  
Duration :

Coinfections :

Liver disease/Malignancy

Haematological abnormalities

Immunodeficiency/Steroids

Renal disease /Meningitis/Septicaemia

Mode of transmission:

Food borne(milk,meat,vegetables)

Fruits & beverages, icecream , sandwich

Water borne:

Person to person(contact)

Animal to human:(milk,undercooked meat)

Community acquired:

Past history :

Treatment history : Antibiotics/laxatives

General examination :

Dehydration: mild/moderate/severe

Systemic examination:

CVS:

RS:

Abdomen:

CNS: